

FORM PTO-1390 (REV. 10-2000)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371		ATTORNEY'S DOCKET NUMBER 20493P	
		U.S. APPLICATION NO. (If known, see 37 CFR 1.5) <div style="font-size: 1.5em; font-weight: bold;">10/031014</div>	
INTERNATIONAL APPLICATION NO. PCT/US00/18733	INTERNATIONAL FILING DATE 07/10/2000	PRIORITY DATE CLAIMED 07/14/1999	
TITLE OF INVENTION MELANIN-CONCENTRATING HORMONE RECEPTOR			
APPLICANT(S) FOR DO/EO/US ANDREW D. HOWARD			
<p>Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:</p> <ol style="list-style-type: none"> 1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. 2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. 3. <input type="checkbox"/> This is an express request to begin national examination procedures [35 U.S.C. 371(f)] at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(l). 4. <input checked="" type="checkbox"/> A proper Demand for International Preliminary Examination was made and the US was elected by the expiration of the 19th month from the earliest claimed priority date (PCT Article 31). 5. <input checked="" type="checkbox"/> A copy of the International Application as filed [35 U.S.C. 371(c)(2)]. <ol style="list-style-type: none"> a. <input checked="" type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau). b. <input type="checkbox"/> has been communicated by the International Bureau. c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US). 6. <input type="checkbox"/> An English language translation of the International Application as filed [35 U.S.C. 371(c)(2)]. 7. <input type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 [35 U.S.C. 371(c)(3)]. <ol style="list-style-type: none"> a. <input type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau). b. <input type="checkbox"/> have been communicated by the International Bureau. c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. d. <input type="checkbox"/> have not been made and will not be made. 8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 [35 U.S.C. 371(c)(3)]. 9. <input checked="" type="checkbox"/> An oath or declaration of the inventor(s) [35 U.S.C. 371(c)(4)]. 10. <input type="checkbox"/> An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 [35 U.S.C. 371(c)(5)]. <p>Items 11 to 16 below concern other document(s) or information included:</p> <ol style="list-style-type: none"> 11. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 12. <input checked="" type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 13. <input checked="" type="checkbox"/> A FIRST preliminary amendment. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment. 14. <input type="checkbox"/> A substitute specification. 15. <input type="checkbox"/> A change of power of attorney and/or address letter. 16. <input checked="" type="checkbox"/> Other items or information: Sequence Listing, paper and computer readable copies. 			

EXPRESS MAIL CERTIFICATE


DATE OF DEPOSIT 1-10-2002

EXPRESS MAIL NO. EM230307798 US

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS
 BEING DEPOSITED WITH THE UNITED STATES POSTAL
 SERVICE AS EXPRESS MAIL "POST OFFICE TO
 ADDRESSEE" BEFORE 5 P.M. ON THE ABOVE DATE IN
 AN ENVELOPE ADDRESSED TO ASSISTANT COMMISSIONER
 FOR PATENTS, WASHINGTON, D.C. 20231.

MAILED BY AB. Crowley

DATE 1/10/02

U.S. APPLICATION NO. (If known, see 37 CFR 1.5)		INTERNATIONAL APPLICATION NO.		ATTORNEYS DOCKET NUMBER	
10/031014		PCT/US00/18733		20493P	
17. <input checked="" type="checkbox"/> The following fees are submitted:				CALCULATIONS	PTO USE ONLY
BASIC NATIONAL FEE [37 CFR 1.492(a)(1)-(5)]:					
Neither international preliminary examination fee (37 CFR 1.482) nor international search fee [37 CFR 1.445(a)(2)] paid to USPTO and International Search Report not prepared by the EPO or JPO.....				\$1,040.00	
International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO.....				\$890.00	
International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee [37 CFR 1.445(a)(2)] paid to USPTO.....				\$740.00	
International preliminary examination fee paid to USPTO (37 CFR 1.482) but all claims did not satisfy provisions of PCT Article 33(1)-(4).....				\$710.00	
International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(1)-(4).....				\$100.00	
ENTER APPROPRIATE BASIC FEE AMOUNT =				\$710.00	
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date [37 CFR 1.492(e)].				\$0.00	
Claims	Number Filed	Number Extra	Rate		
Total Claims	18 - 20 =	0	X \$18.00	\$0.00	
Independent Claims	5 - 3 =	2	X \$84.00	\$168.00	
Multiple dependent claim(s) (if applicable)			+ \$280.00	\$0.00	
TOTAL OF ABOVE CALCULATIONS =				\$878.00	
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.					
SUBTOTAL =				\$878.00	
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date [37 CFR 1.492(f)].				+	\$0.00
TOTAL NATIONAL FEE =				\$878.00	
Fee for recording the enclosed assignment [37 CFR 1.21(h)]. The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property.				+	
TOTAL FEES ENCLOSED =				\$878.00	
				Amount to be refunded	
				charged	
a. <input type="checkbox"/> A check in the amount of \$ _____ to cover the above fees is enclosed.					
b. <input checked="" type="checkbox"/> Please charge my Deposit Account No. <u>13-2755</u> in the amount of <u>\$878.00</u> to cover the above fees. A duplicate copy of this sheet is enclosed.					
c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to the Deposit Account No. <u>13-2755</u> . A duplicate copy of this sheet is enclosed.					
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive [37 CFR 1.137(a) or (b)] must be filed and granted to restore the application to pending status.					
SEND ALL CORRESPONDENCE TO:					
MERCK & CO., INC. Patent Department, RY60-30 P.O. Box 2000 126 East Lincoln Avenue Rahway, New Jersey 07065-0970			 SIGNATURE		
DATE: <u>January 10 2002</u>			NAME: <u>Sheldon O. Heber</u>		
PHONE #: <u>(732) 594-1958</u>			REGISTRATION NUMBER: <u>38,179</u>		

10/031014

PATENT

531 Rec'd PCT/PT 10 JAN 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Howard

Serial No.: TBA - Case No.: 20493P

Art Unit:

Filed:

Examiner:

For: MELANIN-CONCENTRATING
HORMONE RECEPTORPRELIMINARY AMENDMENTAssistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Please amend the claims by canceling claims 2, 3, 18, 20, 21, 23-27, and 29-33 without prejudice to future prosecution and replacing claims as follows:

1. (Amended Once) A purified nucleic acid comprising a nucleotide sequence encoding for SEQ. ID. NO. 4, SEQ. ID. NO. 6 or SEQ. ID. NO. 8.
4. (Amended Once) The nucleic acid of claim 1, wherein said nucleic acid comprises SEQ. ID. NO. 7.
9. (Amended Once) An expression vector comprising a nucleotide sequence encoding for SEQ. ID. NO. 4, SEQ. ID. NO. 6 or SEQ. ID. NO. 8.
11. (Amended Once) The expression vector of claim 10, wherein said nucleotide sequence encodes for SEQ. ID. NO. 8.

EXPRESS MAIL CERTIFICATE

DATE OF DEPOSIT 1-10-2002EXPRESS MAIL NO. EM230307798 US

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS
BEING DEPOSITED WITH THE UNITED STATES POSTAL
SERVICE AS EXPRESS MAIL "POST OFFICE TO
ADDRESSEE" BEFORE 5 P.M. ON THE ABOVE DATE IN
AN ENVELOPE ADDRESSED TO ASSISTANT COMMISSIONER
FOR PATENTS, WASHINGTON, D.C., 20231.

MAILED BY [Signature]DATE 1/10/02

19. (Amended Once) A polypeptide comprising an amino acid sequence of SEQ. ID. NO. 4, SEQ. ID. NO. 6 or SEQ. ID. NO. 8, wherein said polypeptide is substantially free of associated proteins.


22. (Amended Once) A method for screening for a compound able to bind a MCH receptor comprising the steps of:

- (a) expressing a polypeptide comprising the amino acid sequence of SEQ. ID. NO. 4 or SEQ. ID. NO. 6;
- (b) providing to said polypeptide a test preparation comprising one or more test compounds; and
- (c) measuring the ability of said test preparation to bind to said polypeptide.

Remarks

Claims 2, 3, 18, 20, 21, 23-27 and 29-33 were cancelled and claims 1, 4, 9, 11, 19 and 22 were amended. The cancellation and amendment of claims is without prejudice to future prosecution. Please charge deposit account 13-2755 for fees due in connection with this amendment.

Respectfully submitted,

By 
Sheldon O. Heber
Reg. No. 38,179
Attorney for Applicants

Merck & Co., Inc.
P.O. Box 2000
Rahway, NJ 07065-0907
(732) 594-1958

Version with Markings to Show Changes Made

Changes to the Claims:

1. (Amended Once) A purified nucleic acid comprising a nucleotide sequence encoding for ~~[at least 5 contiguous amino acids of]~~ SEQ. ID. NO. 4, SEQ. ID. NO. 6 or SEQ. ID. NO. 8.

4. (Amended Once) The nucleic acid of claim 1, wherein said nucleic acid comprises ~~[at least about 18 contiguous nucleotides of]~~ SEQ. ID. NO. 7.

9. (Amended Once) An expression vector comprising a nucleotide sequence encoding for ~~[a polypeptide comprising at least 5 contiguous amino acids of]~~ SEQ. ID. NO. 4, SEQ. ID. NO. 6 or SEQ. ID. NO. 8.

11. (Amended Once) The expression vector of claim 10, wherein said nucleotide sequence encodes for ~~[at least 9 contiguous amino acids of]~~ SEQ. ID. NO. 8.

19. (Amended Once) A polypeptide comprising an amino acid sequence ~~[encoding for at least about 9 contiguous amino acids]~~ of SEQ. ID. NO. 4, SEQ. ID. NO. 6 or SEQ. ID. NO. 8, wherein said polypeptide is substantially free of associated proteins.

22. (Amended Once) A method for screening for a compound able to bind a MCH receptor comprising the steps of:

(a) expressing a polypeptide comprising the amino acid sequence of SEQ. ID. NO. 4[,] or SEQ. ID. NO. 6[,] or a fragment thereof, from recombinant nucleic acid, ~~provided that said fragment comprises at least about 9 contiguous amino acids of SEQ. ID. NO. 8];~~

- (b) providing to said polypeptide a test preparation comprising one or more test compounds; and
- (c) measuring the ability of said test preparation to bind to said polypeptide.

531 Rec'd PCT/PT 10 JAN 2002

TITLE OF THE INVENTION

MELANIN-CONCENTRATING HORMONE RECEPTOR

CROSS-REFERENCE TO RELATED APPLICATIONS

- 5 The present application claims priority to U.S. Serial No. 60/143,706, filed July 14, 1999, hereby incorporated by reference herein.

FIELD OF THE INVENTION

- 10 The present invention relates to the melanin-concentrating hormone receptor, methods of screening for compounds active at the melanin-concentrating hormone receptor, and methods of using such compounds to achieve a beneficial effect.

BACKGROUND OF THE INVENTION

- 15 The references cited herein are not admitted to be prior art to the claimed invention.

- Neuropeptides present in the hypothalamus play a major role in mediating the control of body weight. (Flier, *et al.*, 1998. *Cell*, 92, 437-440.) Melanin-concentrating hormone (MCH) is a cyclic 19-amino acid neuropeptide synthesized as part of a larger pre-prohormone precursor in the hypothalamus which also encodes neuropeptides NEI and NGE. (Nahon, *et al.*, 1990. *Mol. Endocrinol.* 4, 632-637.) MCH was first identified in salmon pituitary, and in fish MCH affects melanin aggregation thus affecting skin pigmentation. In trout and in eels MCH has also been shown to be involved in stress induced or CRF-stimulated ACTH release. (Kawauchi, *et al.*, 1983. *Nature* 305, 321-323.)
- 20 In humans two genes encoding MCH have been identified that are expressed in the brain. (Breton, *et al.*, 1993. *Mol. Brain Res.* 18, 297-310.) In mammals MCH has been localized primarily to neuronal cell bodies of the hypothalamus which are implicated in the control of food intake, including perikarya of the lateral hypothalamus and zona inertia. (Knigge, *et al.*, 1996. *Peptides* 17, 1063-1073.)
- 25 Pharmacological and genetic evidence suggest that the primary mode of MCH action is to promote feeding (orexigenic). MCH mRNA is up regulated in fasted mice and rats, in the *ob/ob* mouse (Qu, *et al.*, 1996 *Nature* 380, 243-247), and in mice with targeted disruption in the gene for neuropeptide Y (NPY). (Erickson, *et*
- 30
- 35

al., 1996. *Nature* 381, 415-418.) Injection of MCH centrally (ICV) stimulates food intake and MCH antagonizes the hypophagic effects seen with α melanocyte stimulating hormone (α MSH). (Qu, *et al.*, 1996. *Nature* 380, 243-247.) MCH deficient mice are lean, hypophagic and have increased metabolic rate. (Shimada, *et al.*, 1998. *Nature* 396, 670-673.)

MCH action is not limited to modulation of food intake as effects on the hypothalamic-pituitary-axis have been reported. (Nahon, 1994. *Critical Rev. in Neurobiol.* 8, 221-262.) MCH may be involved in the body response to stress as MCH can modulate the stress-induced release of CRF from the hypothalamus and ACTH from the pituitary. In addition, MCH neuronal systems may be involved in reproductive or maternal function.

SUMMARY OF THE INVENTION

The present application features two different forms of the human MCH receptor: (1) MCH-R2 and (2) MCH-R3. Such MCH receptors provide a target for achieving a beneficial affect in a patient and facilitate the screening of compounds that modulate MCH receptor activity or expression. Beneficial effects that can be obtained include increasing appetite, decreasing appetite, and reducing stress.

The MCH receptor is a G protein-coupled receptor that transduces an intracellular signal upon MCH binding. The ability of MCH-R1, a shorter length derivative of MCH-R2 and MCH-3 to couple to a G_i protein is illustrated in Example 3, *infra*.

MCH-R1, MCH-R2 and MCH-R3 are structurally related polypeptides differing by the presence of additional amino acids at the extracellular amino terminus. MCH-R2 has an additional 64 amino acids at its amino terminus compared to MCH-R1. MCH-R3 has an additional 5 amino acids at its amino terminus compared to MCH-R2, and an additional 69 amino acids at its amino terminus compared to MCH-R1. The nucleic acid and amino acid sequences of MCH-R1, MCH-R2, and MCH-R3 are provided for in SEQ. ID. NOs. 1, 2, 3, 4, 5, and 6 (see Example 1 *infra*). The additional nucleic acids and amino acid regions present in MCH-R3 compared to MCH-R1 is shown in SEQ. ID. NOs. 7 and 8.

Assays measuring MCH receptor activity can employ MCH-R3 or MCH-R2. MCH-R3 is believed to be a naturally occurring MCH receptor since it has the first in frame ATG start codon in the cDNA, while MCH-R1 and MCH-R2 appear

to be shorter-length versions of MCH-R3. MCH-R2 has the best ribosome initiation sequence 5' to the ATG start, 5 of the 9 nts match the optimal sequence: GCC GCC (A or G)CC ATG (SEQ. ID. NO. 10) which could result in MCH-R2 being the highest expressed form of the MCH receptor.

5 Thus, a first aspect of the present invention describes a purified nucleic acid comprising a nucleotide sequence encoding for at least 5 contiguous amino acids of SEQ. ID. NO. 8. In preferred embodiments the nucleotide sequence encodes for at least 9, at least 18, at least 27 or at least 36 contiguous amino acids of SEQ. ID. NO. 8; the nucleotide sequence encodes for amino acids 1-5 of SEQ. ID. NO. 8; the
10 nucleic acid comprises at least about 18, at least 27, or at least 54 contiguous nucleotides of SEQ. ID. NO. 7; and the nucleic acid comprises or consists of the nucleotide sequence of SEQ. ID. NO. 3, SEQ. ID. NO. 4, SEQ. ID. NO. 5, SEQ. ID. NO. 6, or SEQ. ID. NO. 9.

15 A "purified nucleic acid" represents at least 5% of the total nucleic acid present in a sample or preparation. In preferred embodiments, the purified nucleic acid represents at least about 50%, at least about 75%, and at least about 95% of the total nucleic acid a sample or preparation. Reference to "purified nucleic acid" does not require that the nucleic acid have undergone any purification and may include, for example, chemically synthesized nucleic acid that has not been purified.

20 Another aspect of the present invention describes an expression vector able to express a polypeptide comprising at least 5 contiguous amino acids of SEQ. ID. NO. 8. The expression vector provides one or more regulatory elements functionally coupled to nucleic acid encoding for the polypeptide such that the polypeptide can be transcribed and translated when present in a suitable host.
25 Preferably, the expression vector contains an exogenous promoter transcriptionally coupled to the nucleic acid encoding the polypeptide.

30 In preferred embodiments the expression vector comprises nucleic acid encoding for at least 9, at least 18, at least 27 or at least 36 contiguous amino acids of SEQ. ID. NO. 8; the expression vector comprises nucleic acid encoding for amino acids 1-5 of SEQ. ID. NO. 8; the expression vector comprises at least about 18, at least 27, or at least 54 contiguous nucleotides of SEQ. ID. NO. 7; and the expression vector comprises the nucleotide sequence of SEQ. ID. NO. 3, SEQ. ID. NO. 5, or SEQ. ID. NO. 9; and the expression vector comprises a nucleotide sequence encoding for polypeptide comprising or consisting of SEQ. ID. 4 or SEQ. ID. NO. 6.

Another aspect of the present invention describes a recombinant cell comprising an expression vector encoding for a polypeptide comprising at least 5 contiguous amino acids of SEQ. ID. NO. 8. The polypeptide can be expressed from the vector when present in the recombinant cell.

5 Another aspect of the present invention describes a method of preparing a MCH receptor polypeptide comprising the step of growing a recombinant cell containing an expression vector comprising nucleic acid encoding for a MCH receptor polypeptide under conditions suitable for the expression of the MCH receptor polypeptide. Preferably, the expressed MCH receptor polypeptide is purified.

10 Another aspect of the present invention describes a purified nucleic acid comprising a region of 20 contiguous nucleotides, wherein at least 16 nucleotides present in the region hybridizes to a complementary region of 20 contiguous nucleotides present in SEQ. ID. NO. 7 or the complement thereof. In preferred embodiments the nucleic acid comprises a region of 20 contiguous nucleotides
15 wherein at least 17, at least 18, at least 19, and 20, nucleotides present in the region hybridize to a complementary region of 20 contiguous nucleotides present in SEQ. ID. NO. 7 or the complement thereof.

Another aspect of the present invention describes a polypeptide comprising an amino acid sequence encoding for at least about 9 contiguous amino
20 acids of SEQ. ID. NO. 8, wherein the polypeptide is substantially free of associated proteins. In preferred embodiments the polypeptide comprises at least 18, at least 27, or at least 36 contiguous amino acids of SEQ. ID. NO. 8; and the polypeptide comprises or consists of the amino acid sequence of SEQ. ID. NO. 4 or SEQ. ID. NO. 6.

25 "Substantially free from associated proteins" means that the polypeptide is at least about 50%, preferably at least about 75%, and more preferably at least about 95% free from other cell membrane proteins which are normally found in a living mammalian cell expressing a MCH receptor.

Another aspect of the present invention describes a method for
30 screening for a compound able to bind a MCH receptor. The method involves the following: (a) expressing a polypeptide comprising MCH-R2, MCH-R3, or a fragment thereof, from recombinant nucleic acid, provided that the fragment comprises at least about 9 contiguous amino acids of SEQ. ID. NO. 8; (b) providing to the polypeptide a test preparation comprising one or more test compounds; and (c)
35 measuring the ability of the test preparation to bind to the polypeptide.

In different embodiments steps (b) and (c) are performed *in vitro*; steps (a), (b) and (c) are preformed using a whole cell; the polypeptide is expressed from an expression vector; the polypeptide comprises or consists of the amino sequence of SEQ. ID. NO. 6; and the method is performed where said step (b) further comprises the presence of a labeled MCH, and step (c) measures the ability of said test preparation to inhibit binding of said labeled MCH to said polypeptide.

Another aspect of the present invention describes a method for screening for a compound able to modulate MCH receptor activity. The method involves (a) contacting a cell line expressing recombinant nucleic acid encoding for a MCH receptor comprising or consisting of the amino acid sequence of MCH-R2 or MCH-R3 with a test preparation comprising one or more test compounds; and (b) measuring the effect of the test preparation on the activity of the receptor.

In preferred embodiments the MCH receptor comprises or consists of the amino acid sequence of SEQ. ID. NO. 4 or SEQ. ID. NO. 6; and the method further comprises the presence of an MCH receptor agonist.

Another aspect of the present invention describes a method for suppressing appetite comprising the step of administering to a patient an effective amount of means for decreasing MCH receptor expression targeting a nucleic acid region within SEQ. ID. NO. 7. Such "means" are provided for by the materials and structures described herein, and equivalents thereof. Preferred means are antisense nucleic acid and enzymatic nucleic acid. "Targeting a nucleic acid region within SEQ. ID. NO. 7" indicates that the means for decreasing MCH receptor activity contains a region substantially complementary to a segment of SEQ. ID. NO. 7 such that it hybridizes to the target under physiological conditions.

Other features and advantages of the present invention are apparent from the additional descriptions provided herein including the different examples. The provided examples illustrate different components and methodology useful in practicing the present invention. The examples do not limit the claimed invention. Based on the present disclosure the skilled artisan can identify and employ other components and methodology useful for practicing the present invention.

DETAILED DESCRIPTION OF THE INVENTION

The present application describes a longer length version of MCH-R1 which is believed to be a natural MCH receptor (MCH-R3) and a slightly shorter version thereof (MCH-R2). MCH-R2 and MCH-R3 have a variety of different uses

including being a target of receptor cloning, a target for receptor identification, a target for the production of antibodies, and a target for receptor modulation.

Additional uses include being used in assays to determine the ability of a test preparation to modulate MCH receptor activity and in gene therapy.

5 Nucleic acid and amino acid sequences corresponding to MCH-R1 have been characterized in the art as encoding for a somatostatin-like receptor (SLC-1). For example, human and rat SLC-1 are described by Lakaye, *et al.*, 1998. *Biochimica et Biophysica ACTA* 1401:216-220 (which is not admitted to be prior art to the claimed invention). Additionally, a receptor characterized as a human
10 somatostatin-like receptor is referenced in International Publication No. WO 96/18651 and Kolakowski, *et al.*, 1996. *FEBS Letters* 398, 253-258, and an apparent splice variant is referenced in European Publication No. EP 0 848 060 A2 and International Publication No. WO 99/28492 (not admitted to be prior art to the claimed document).

15 A clone expressing the physiological correct receptor facilitates finding useful agonists or antagonists of the human MCH receptor. In contrast, use of a clone expressing a receptor with a physiologically incorrect MET start would lead to the use of an altered receptor protein, the use of which could be less predictive in finding compounds able to modulate MCH receptor activity.

20 The MCH receptor provides a target to achieve different beneficial effects in a patient. Preferably, MCH receptor activity is modulated to achieve one or more of the following: weight loss, weight gain, treat cancer (*e.g.*, colon or breast), reduce pain, treat diabetes, reduce stress, or treat sexual dysfunction.

 Modulation of MCH receptor activity can be achieved by evoking a
25 response at the MCH receptor or by altering a response evoked by an MCH receptor agonist or antagonist. Compounds modulating MCH receptor activity include agonists, antagonists, and allosteric modulators. Generally, MCH receptor antagonists and allosteric modulators negatively affecting activity will be used to achieve weight loss, treat cancer (*e.g.*, colon or breast), reduce pain, reduce stress, and/or treat sexual
30 dysfunction; and MCH receptor agonists and allosteric modulators positively affecting activity will be used to produce a weight gain.

 Preferably, MCH receptor activity is modulated to achieve a weight loss or to treat diabetes in a patient. Diabetes mellitus can be treated by modulating MCH receptor activity to achieve, for example, one or both of the following:
35 enhancing glucose tolerance or decreasing insulin resistance.

Excessive body weight is a contributing factor to different diseases, including hypertension, diabetes, dyslipidemias, cardiovascular disease, gall stones, osteoarthritis, and certain forms of cancers. Bringing about a weight loss can be used, for example, to reduce the likelihood of such diseases and as part of a treatment for such diseases. Weight reduction can be achieved by modulating MCH receptor activity to obtain, for example, one or more of the following effects: reducing appetite, increasing metabolic rate, reducing fat intake, or reducing carbohydrate craving.

Facilitating a weight gain, maintenance in weight, or appetite increase is particularly useful for a patient having a disease or disorder, or under going a treatment, accompanied by weight loss. Examples of diseases or disorders accompanied by weight loss include anorexia, bulimia, cancer cachexia, AIDS, wasting, cachexia, and wasting in frail elderly. Examples of treatments accompanied by weight loss include chemotherapy, radiation therapy, temporary or permanent immobilization, and dialysis.

MCH RECEPTOR NUCLEIC ACID

The guidance provided in the present application can be used to obtain the MCH receptor from different sources such as mammalian sources and artificially produced MCH receptor. Identification and isolation of MCH receptor nucleic acid is preferably performed using MCH-R3 nucleic acid information. Such nucleic acid information can be used to facilitate obtaining a full length receptor.

Obtaining nucleic acids encoding for related polypeptides is facilitated using sets of degenerative probes and primers and by the proper selection of hybridization conditions. Sets of degenerative probes and primers are produced taking into account the degeneracy of the genetic code. Adjusting hybridization conditions is useful for controlling probe or primer specificity to allow for hybridization to nucleic acids having similar sequences.

Techniques employed for hybridization detection and PCR cloning are well known in the art. Nucleic acid detection techniques are described, for example, in Sambrook, *et al.*, in *Molecular Cloning, A laboratory Manual*, 2nd Edition, Cold Spring Harbor Laboratory Press, 1989. PCR cloning techniques are described, for example, in White, *Methods in Molecular Cloning*, volume 67, Humana Press, 1997.

MCH receptor probes and primers can be used to screen nucleic acid libraries containing, for example, genomic DNA or cDNA. Such libraries are

commercially available, and can be produced using techniques such as those described in Ausubel, *Current Protocols in Molecular Biology*, John Wiley, 1987-1998.

Detection of probe hybridization is facilitated through the use of a detectable label.

Starting with a MCH receptor obtained from a particular source,
5 derivatives can be produced having MCH receptor activity. Such derivatives include polypeptides having amino acid substitutions, additions and deletions. Such changes should be made outside of the MCH binding domain and in a manner not altering the tertiary structure. Amino acids are classified into certain types based on the structure of their R-groups. Substituting different amino acids within a particular group, such
10 as substituting valine for leucine, arginine for lysine, and asparagine for glutamine may not cause a change in functionality of the polypeptide.

Starting with a particular MCH receptor amino acid sequence and the known degeneracy of the genetic code, a large number of different encoding nucleic acid sequences can be obtained. The degeneracy of the genetic code arises because
15 almost all amino acids are encoded for by different combinations of nucleotide triplets. The translation of a particular codon into a particular amino acid is well known in the art (see, e.g., Lewin *GENES IV*, p. 119, Oxford University Press, 1990).

Nucleic acid having a desired sequence can be synthesized using chemical and biochemical techniques. Examples of such techniques are described in
20 Ausubel, *Current Protocols in Molecular Biology*, John Wiley, 1987-1998, and Sambrook, *et al.*, in *Molecular Cloning, A Laboratory Manual*, 2nd Edition, Cold Spring Harbor Laboratory Press, 1989.

Biochemical synthesis techniques involve the use of nucleic acid replicating conditions. Preferably, such techniques involve the use of a plasmid
25 containing MCH receptor nucleic acid and a compatible host cell. Examples of suitable techniques are provided by Ausubel, *Current Protocols in Molecular Biology*, John Wiley, 1987-1998, and Sambrook, *et al.*, in *Molecular Cloning, A Laboratory Manual*, 2nd Edition, Cold Spring Harbor Laboratory Press, 1989.

Nucleic acid obtained from a particular source can be altered using
30 different techniques such as those provided for in Ausubel, *Current Protocols in Molecular Biology*, John Wiley, 1987-1998, and Sambrook, *et al.*, in *Molecular Cloning, A laboratory Manual*, 2nd Edition, Cold Spring Harbor Laboratory Press, 1989.

RECOMBINANT EXPRESSION

MCH receptor polypeptides such as a MCH receptor, a MCH receptor fragment, and a polypeptide containing the MCH receptor or MCH receptor fragment can be expressed from recombinant nucleic acid *in vivo* using a suitable host or *in vitro* using a translation system. Recombinantly expressed MCH receptor polypeptides are preferably used in assays to screen for compounds that bind to the MCH receptor and modulate the activity of the receptor.

Techniques for nucleic acid expression are well known in the art and can be applied to different nucleic acids encoding for different MCH receptor polypeptides. Examples of techniques for expression of nucleic acids are provided in Ausubel, *Current Protocols in Molecular Biology*, John Wiley, 1987-1998, and Sambrook, *et al.*, in *Molecular Cloning, A Laboratory Manual*, 2nd Edition, Cold Spring Harbor Laboratory Press, 1989.

Preferably, expression is achieved in a host cell using an expression vector. An expression vector contains nucleic acid encoding for a desired polypeptide along with regulatory elements for proper transcription and processing. Generally, the regulatory elements that are present include a transcriptional promoter, a ribosome binding site, a terminator, and an optionally present operator. Another preferred element is a polyadenylation signal providing for processing in eukaryotic cells. Examples of expression vectors are cloning vectors, modified cloning vectors, specifically designed plasmids and viruses.

Preferably, an expression vector also contains an origin of replication for autonomous replication in a host cell, a selectable marker, a limited number of useful restriction enzyme sites, and a potential for high copy number.

The skilled artisan can readily identify expression vectors providing suitable levels of MCH receptor polypeptide expression in different hosts. A variety of mammalian expression vectors are well known in the art including pcDNA3 (Invitrogen), pMC1neo (Stratagene), pXT1 (Stratagene), pSG5 (Stratagene), EBO-pSV2-neo (ATCC 37593) pBPV-1(8-2), (ATCC 37110), pdBPV-MMTneo(342-12) (ATCC 37224), pRSVgpt (ATCC 37199), pRSVneo (ATCC 37198), pSV2-dhfr (ATCC 37146), pUCTag (ATCC 37460), pCI-neo (Promega) and .lambda.ZD35 (ATCC 37565). A variety of bacterial expression vectors are well known in the art including pET11a (Novagen), lambda gt11 (Invitrogen), pcDNAII (Invitrogen), and pKK223-3 (Pharmacia). A variety of fungal cell expression vectors are well known in the art including pYES2 (Invitrogen), Pichia expression vector (Invitrogen). A variety

of insect cell expression vectors are well known in the art including Blue Bac III (Invitrogen).

Recombinant host cells may be prokaryotic or eukaryotic. Examples of recombinant host cells include the following: bacteria such as *E. coli*; fungal cells such as yeast; mammalian cells such as human, bovine, porcine, monkey and rodent; and insect cells such as *Drosophila* and silkworm derived cell lines. Commercially available mammalian cell lines include L cells L-M(TK.sup.-) (ATCC CCL 1.3), L cells L-M (ATCC CCL 1.2), 293 (ATCC CRL 1573), Raji (ATCC CCL 86), CV-1 (ATCC CCL 70), COS-1 (ATCC CRL 1650), COS-7 (ATCC CRL 1651), CHO-K1 (ATCC CCL 61), 3T3 (ATCC CCL 92), NIH/3T3 (ATCC CRL 1658), HeLa (ATCC CCL 2), C127I (ATCC CRL 1616), BS-C-1 (ATCC CCL 26) and MRC-5 (ATCC CCL 171).

Expression vectors may be introduced into host cells using standard techniques. Examples of such techniques include transformation, transfection, lipofection, protoplast fusion, and electroporation.

MCH receptor nucleic acid can be expressed in a cell without the use of an expression vector using, for example, synthetic mRNA or native mRNA. Additionally, mRNA can be translated in various cell-free systems such as wheat germ extracts and reticulocyte extracts, as well as in cell based systems, such as frog oocytes. Introduction of mRNA into cell based systems can be performed, for example, by microinjection.

MCH-R3 PROBES

Detection probes for MCH-R3 preferably contain a region targeted to a SEQ. ID. NO. 7 nucleic acid region. The targeted region has at least 16 nucleotides that hybridize (*e.g.*, A-T and G-C hybridization) to a complementary region of 20 contiguous nucleotides present in SEQ. ID. NO. 7 or the complement thereof. Such probes can contain additional nucleic acid outside the targeted region to, for example, provide for increased specificity or the serve another purpose such as being a reporter sequence or a capture sequence.

Probes for the MCH receptor can specifically hybridize to MCH receptor target nucleic acid under appropriate hybridization conditions (*i.e.*, distinguish target nucleic acid from one or more non-target nucleic acid molecules). Hybridization occurs through complementary nucleotide bases present on the probe or primer and MCH receptor nucleic acid. Hybridization conditions determine whether

two molecules have sufficiently strong interactions with each other to form a stable hybrid.

Probes are composed of nucleic acids or derivatives thereof such as modified nucleic acid and peptide nucleic acid. Modified nucleic acid includes nucleic acid with one or more altered sugar groups, altered internucleotide linkages, and/or altered nucleotide purine or pyrimidine bases. Detection of probe hybridization is facilitated through the use of a detectable label. Examples of detectable labels include luminescent, enzymatic, and radioactive labels. References describing modified nucleic acid include WO 98/02582, U.S. Patent No. 5,859,221 and U.S. Patent No. 5,852,188, each of which are hereby incorporated by reference herein.

The degree of interaction between two molecules that hybridize together is reflected by the T_m of the produced hybrid. The higher the T_m the stronger the interactions and the more stable the hybrid. T_m is effected by numerous factors well known in the art such as the degree of complementarity, the type of complementary bases present (*e.g.*, A-T hybridization versus G-C hybridization), and the structure of the nucleic acid backbones. *E.g.*, Sambrook, *et al.*, in *Molecular Cloning, A Laboratory Manual*, 2nd Edition, Cold Spring Harbor Laboratory Press, 1989.

Stable hybrids are formed when the T_m of a hybrid is greater than the temperature employed under a particular set of hybridization assay condition. The degree of specificity of a probe can be varied allowing for the identification of related sequences by adjusting the hybridization stringency conditions. Examples of stringency conditions are provided in Sambrook, *et al.*, in *Molecular Cloning, A Laboratory Manual*, 2nd Edition, Cold Spring Harbor Laboratory Press, 1989.

An example of high stringency conditions is as follows:
Prehybridization of filters containing DNA is carried out for 2 hours to overnight at 65°C in buffer composed of 6X SSC, 5X Denhardt's solution, and 100 µg/ml denatured salmon sperm DNA. Filters are hybridized for 12 to 48 hours at 65°C in prehybridization mixture containing 100 µg/ml denatured salmon sperm DNA and 5-20 X 10⁶ cpm of ³²P-labeled probe. Washing of filters is done at 37°C for 1 hour in a solution containing 2X SSC, 0.1% SDS. This is followed by a wash in 0.1X SSC, 0.1% SDS at 50°C for 45 minutes before autoradiography. Other procedures using conditions of high stringency would include, for example, either a hybridization step carried out in 5XSSC, 5X Denhardt's solution, 50% formamide at 42°C for 12 to 48

hours or a washing step carried out in 0.2X SSPE, 0.2% SDS at 65°C for 30 to 60 minutes.

MCH-R2/MCH-R3 ANTIBODIES

5 Antibodies recognizing a MCH-R2 or MCH-R3 polypeptide can be produced using a SEQ. ID. NO. 8 polypeptide or a fragment thereof as an immunogen. Fragments of SEQ. ID. NO. 8 polypeptides used as an immunogen should be at least 9 amino acids in length. Antibodies to MCH-R3 can be used, for example, to identify and isolate MCH-R3 polypeptides. Examples of techniques for
10 producing and using antibodies are described in Ausubel, *Current Protocols in Molecular Biology*, John Wiley, 1987-1998, Harlow, *et al.*, *Antibodies, A Laboratory Manual*, Cold Spring Harbor Laboratory, 1988, and Kohler, *et al.*, *Nature* 256:495-497 (1975).

MCH RECEPTOR BINDING ASSAY

15 MCH-R2, MCH-R3, and fragments thereof, can be used in a binding assay to screen compounds able to bind to the MCH receptor. Different types of assay formats can be employed including the use of labeled compounds and/or the use of a labeled MCH ligand.

20 The particular amino acid sequence involved in MCH receptor binding can be readily identified by using labeled MCH and different receptor fragments. Different strategies can be employed to select fragments to be tested to narrow down the binding region. Examples of such strategies include testing consecutive fragments about 15 amino acids in length starting at the N-terminus, and testing longer length
25 fragments. If longer length fragments are tested, a fragment binding MCH can be subdivided to further locate the MCH binding region. Fragments used for binding studies can be generated using recombinant nucleic acid techniques.

 MCH ligands able to bind to the MCH receptor can readily be designed based on the structure of MCH and the ability of MCH derivatives to bind to the
30 MCH receptor. Examples of different polypeptides that appear to be MCH ligands are provided for in U.S. Patent No. 5,849,708, hereby incorporated by reference herein.

 Different types of labels for MCH ligands can be employed. Examples of such labels include radiolabels, luminescent molecules, haptens and enzyme

substrates. The ability of a particular label to interfere with binding can readily be determined by comparing the ability of MCH labeled with the particular label to compete against [¹²⁵I]-MCH binding.

5 Binding assays can be performed using individual compounds or preparations containing different numbers of compounds. A preparation containing different numbers of compounds having the ability to bind to the MCH receptor can be divided into smaller groups of compounds that can be tested to identify the compound(s) binding to the MCH receptor. In an embodiment of the present invention a test preparation containing at least 10 compounds is used in a binding
10 assay.

Binding assays can be performed using recombinantly produced MCH receptor polypeptides present in different environments. Such environments include, for example, cell extracts, and purified cell extracts, containing the MCH receptor polypeptide expressed from recombinant nucleic acid; and also include, for example,
15 the use of a purified MCH receptor polypeptide produced by recombinant means which is introduced into a different environment.

SCREENING FOR MCH RECEPTOR ACTIVE COMPOUNDS

20 Screening for MCH receptor active compounds is facilitated using recombinantly expressed MCH-R2, MCH-R3 or a chimeric receptor containing a fragment thereof functionally coupled to a G protein. Using such recombinantly expressed MCH receptor polypeptides offers several advantages such as the ability to express the receptor in a defined cell system so that a response to MCH receptor active compounds can more readily be differentiated from responses to other
25 receptors. For example, the MCH receptor can be expressed in a cell line such as HEK 293, COS 7, and CHO not normally expressing the receptor by an expression vector, wherein the same cell line without the expression vector or with an expression vector not encoding for a MCH receptor can act as a control.

30 Screening for MCH receptor active compounds is facilitated through the use of a MCH ligand in the assay. The use of a MCH ligand in a screening assay provides for MCH receptor activity. The effect of test compounds on such activity can be measured to identify, for example, allosteric modulators and antagonists. Additionally, such assays can be used to identify agonists.

MCH receptor activity can be measured using different techniques
35 such as detecting a change in the intracellular conformation of the MCH receptor, G

protein activities, and/or intracellular messengers. G protein activities include Gi and Gs. Gi activity can be measured using techniques well known in the art such as a melonaphore assay, assays measuring cAMP production, inhibition of cAMP accumulation, and binding of ^{35}S -GTP. cAMP can be measured using different techniques such as radioimmunoassay and indirectly by cAMP responsive gene reporter proteins.

MCH receptor activity can be measured, for example, by assays measuring the phospholipase C signal transduction pathway. Activity of the phospholipase C signal transduction pathway can be measured using standard techniques such as those measuring intracellular Ca^{2+} . Examples of techniques well known in the art that can be employed to measure Ca^{2+} include the use of dyes such as Fura-2 and the use of Ca^{2+} -bioluminescent sensitive reporter proteins such as aequorin. An example of a cell line employing aequorin to measure G protein activity is HEK293/aeq17. (Button *et al.*, 1993. *Cell Calcium* 14, 663-671, and Feighner *et al.*, 1999. *Science* 284:2184-2188, both of which are hereby incorporated by reference herein.)

Chimeric receptors containing one or more MCH receptor regions functionally coupled to polypeptides from other G proteins can also be used to measure activity. A chimeric MCH receptor contains an N-terminal extracellular domain; a transmembrane domain made up of transmembrane regions, extracellular loop regions, and intracellular loop regions; and an intracellular carboxy terminus domain.

The specificity of G protein coupling is determined by intracellular domain(s). A chimeric G protein coupled receptor can be produced to functionally couple to a particular G protein such as a Gq protein or a Gi protein. Such signal swapping allows for the detection of a receptor activity by measuring Gq or Gi activity. Techniques for producing chimeric receptors and measuring G protein coupled responses are provided for in, for example, International Application No. WO 97/05252, and U.S. Patent No. 5,264,565, both of which are hereby incorporated by reference herein.

Functional assays can be performed using individual compounds or preparations containing different compounds. A preparation containing different compounds where one or more compounds affect MCH receptor or chimeric receptor activity can be divided into smaller groups of compounds to identify the compound(s)

affecting MCH receptor activity. In an embodiment of the present invention a test preparation containing at least 10 compounds is used in a functional assay.

Functional assays can be performed using recombinantly produced MCH receptor polypeptides or chimeric receptor polypeptides present in different environments. Such environments include, for example, cell extracts, and purified cell extracts, containing the MCH receptor polypeptide expressed from recombinant nucleic acid; and the use of a purified MCH receptor polypeptide produced by recombinant means that is introduced into a different environment.

Preferably, recombinantly expressed MCH receptor polypeptide is expressed from an expression vector. More preferably, the recombinantly expressed MCH receptor polypeptide comprises or consists of an amino acid sequence provided for in SEQ. ID. NOs. 4 or 6.

MODULATING MCH RECEPTOR EXPRESSION

MCH receptor expression can be altered as a means for increasing or decreasing MCH receptor activity. Such alterations include inhibiting MCH receptor nucleic acid activity to reduce MCH receptor expression and supplying MCH receptor nucleic acid to increase MCH receptor activity.

Inhibition of MCH Receptor Nucleic Acid Activity

MCH receptor nucleic acid activity can be inhibited using nucleic acids recognizing MCH receptor nucleic acid and affecting the ability of such nucleic acid to be transcribed or translated. Inhibition of MCH receptor nucleic acid activity can be used, for example, in target validation studies looking at appetite and stress in model systems, and to inhibit appetite or stress.

A preferred target for inhibiting MCH receptor translation is mRNA. The ability of mRNA to be translated into a protein can be effected by compounds such as anti-sense nucleic acid and enzymatic nucleic acid.

Anti-sense nucleic acid can hybridize to a region of a target mRNA. Depending on the structure of the anti-sense nucleic acid, anti-sense activity can be brought about by different mechanisms such as blocking the initiation of translation, preventing processing of mRNA, hybrid arrest, and degradation of mRNA by RNase H activity.

Enzymatic nucleic acid can recognize and cleave another nucleic acid molecule. Preferred enzymatic nucleic acids are ribozymes.

General structures for anti-sense nucleic acids and ribozymes and methods of delivering such molecules are well known in the art. Modified and unmodified nucleic acids can be used to exert anti-sense effects. Different types of modifications can effect certain anti-sense activities such as the ability to be cleaved by RNase H, and can effect nucleic acid stability. Examples of references describing different anti-sense molecules and ribozymes, and the use of such molecules are provided in U.S. Patent Nos. 5,849,902, 5,859,221, and 5,852,188, which are each hereby incorporated by reference herein.

Guidelines for pharmaceutical administration in general are provided in, for example, *Remington's Pharmaceutical Sciences 18th Edition*, Ed. Gennaro, Mack Publishing, 1990, and *Modern Pharmaceutics 2nd Edition*, Eds. Banker and Rhodes, Marcel Dekker, Inc., 1990. Nucleic acid can be introduced into cells present in different environments using *in vitro*, *in vivo*, or *ex vivo* techniques.

Increasing MCH Receptor Expression

Nucleic acid coding for the MCH receptor can be used, for example, to cause an increase in appetite and to create a test system (e.g., a transgenic animal) for screening for compounds affecting MCH receptor expression. Nucleic acids can be introduced and expressed in cells present in different environments. Guidelines for pharmaceutical administration in general are provided in, for example, *Remington's Pharmaceutical Sciences 18th Edition*, *supra.* and *Modern Pharmaceutics 2nd Edition*, *supra.* Examples of techniques useful in gene therapy are illustrated in *Gene Therapy & Molecular Biology: From Basic Mechanisms to Clinical Applications*, Ed. Boulikas, Gene Therapy Press, 1998 (hereby incorporated by reference herein).

MODULATING MCH RECEPTOR ACTIVITY

Using the present application as a guide compounds able to modulate MCH receptor activity can be obtained and used to achieve a beneficial effect in a patient. Such effects can be achieved, for example, by altering appetite or relieving stress using a compound active at the MCH receptor.

Altering appetite is particularly useful for gaining weight in an under weight patient or losing weight in an over weight patient. In addition, for example, farm animals can be treated to gain weight. Under weight patients include those having a body weight about 10% or less, 20% or less, and 30% or less, than the lower end of a "normal" weight range or Body Mass Index ("BMI"). Over weight patients

include those having a body weight about 10% or more, 20% or more, 30% or more, or 50% or more, than the upper end of a "normal" weight range or BMI. "Normal" weight ranges are well known in the art and take into account factors such as a patient age, height, and body type.

5 BMI measures your height/weight ratio. It is determined by calculating weight in kilograms divided by the square of height in meters. The BMI "normal" range is 19-22.

Preferably, non-protein MCH receptor antagonists are used to alter MCH receptor activity. Such antagonists are preferably organic compounds
10 comprising one or more aryl or heteroaryl and having a molecule weight between about 150 and 900.

MCH receptor antagonists include compounds binding to the MCH receptor binding site and compounds binding at other sites. Such compounds can be identified using the techniques described herein. Preferably, an MCH receptor
15 antagonist binds with an affinity of at least about 0.001-fold as well [125I]-MCH using the *in vitro* MCH binding assay, or has an IC₅₀ of at least 5 μ M as determined by the *in vitro* MCH binding assay or the melanophore assay (using *e.g.*, MCH at a concentration of 150 nM in 0.1N acetic acid and MCH-R3). In additional
20 embodiments, the antagonist binds at least 0.01-fold, or at least 0.1-fold, as well as [125I]-MCH, or 0.1-fold to 0.05-fold as well as [125I]-MCH using the *in vitro* MCH binding assay; and the MCH receptor antagonist has an IC₅₀ of at least 500 nM.

MCH receptor modulating compounds can be provided in kit. Such a kit typically contains an active compound in dosage forms for administration. A dosage form contains a sufficient amount of active compound such that a beneficial
25 effect can be obtained when administered to a patient during regular intervals, such as 1 to 6 times a day, during the course of 1 or more days.

Preferred kits contain a MCH receptor antagonist provided in dosage forms, wherein the antagonist binds with an affinity of at least about 0.001-fold as well as [125I]-MCH using the *in vitro* MCH binding assay or has an IC₅₀ of at least
30 about 5 μ M. More preferably, the kits contain instructions indicating the use of the dosage form for weight reduction (*e.g.*, obesity or overweight) or stress reduction, and the amount of dosage form to be taken over a specified time period.

DOSING FOR THERAPEUTIC APPLICATIONS

Guidelines for pharmaceutical administration in general are provided in, for example, *Remington's Pharmaceutical Sciences 18th Edition*, Ed. Gennaro, Mack Publishing, 1990, and *Modern Pharmaceutics 2nd Edition*, Eds. Banker and Rhodes, Marcel Dekker, Inc., 1990, both of which are hereby incorporated by reference herein.

Compounds activity active at the MCH receptor having appropriate functional groups can be prepared as acidic or base salts. Pharmaceutically acceptable salts (in the form of water- or oil-soluble or dispersible products) include conventional non-toxic salts or the quaternary ammonium salts that are formed, *e.g.*, from inorganic or organic acids or bases. Examples of such salts include acid addition salts such as acetate, adipate, alginate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, citrate, camphorate, camphorsulfonate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, lactate, maleate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, oxalate, pamoate, pectinate, persulfate, 3-phenylpropionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, tosylate, and undecanoate; and base salts such as ammonium salts, alkali metal salts such as sodium and potassium salts, alkaline earth metal salts such as calcium and magnesium salts, salts with organic bases such as dicyclohexylamine salts, N-methyl-D-glucamine, and salts with amino acids such as arginine and lysine.

MCH receptor active compounds can be administered using different routes including oral, nasal, by injection, transdermal, and transmucosally. Active ingredients to be administered orally as a suspension can be prepared according to techniques well known in the art of pharmaceutical formulation and may contain microcrystalline cellulose for imparting bulk, alginic acid or sodium alginate as a suspending agent, methylcellulose as a viscosity enhancer, and sweeteners/flavoring agents. As immediate release tablets, these compositions may contain microcrystalline cellulose, dicalcium phosphate, starch, magnesium stearate and lactose and/or other excipients, binders, extenders, disintegrants, diluents and lubricants.

When administered by nasal aerosol or inhalation, compositions can be prepared according to techniques well known in the art of pharmaceutical formulation and may be prepared as solutions in saline, employing benzyl alcohol or other suitable

preservatives, absorption promoters to enhance bioavailability, fluorocarbons, and/or other solubilizing or dispersing agents.

The compounds may also be administered in intravenous (both bolus and infusion), intraperitoneal, subcutaneous, topical with or without occlusion, or intramuscular form, all using forms well known to those of ordinary skill in the pharmaceutical arts. When administered by injection, the injectable solutions or suspensions may be formulated using suitable non-toxic, parenterally-acceptable diluents or solvents, such as mannitol, 1,3-butanediol, water, Ringer's solution or isotonic sodium chloride solution, or suitable dispersing or wetting and suspending agents, such as sterile, bland, fixed oils, including synthetic mono- or diglycerides, and fatty acids, including oleic acid.

When rectally administered in the form of suppositories, compositions may be prepared by mixing the drug with a suitable non-irritating excipient, such as cocoa butter, synthetic glyceride esters or polyethylene glycols, which are solid at ordinary temperatures, but liquidify and/or dissolve in the rectal cavity to release the drug.

Suitable dosing regimens for the therapeutic applications of the present invention are selected taking into factors well known in the art including age, weight, sex and medical condition of the patient; the severity of the condition to be treated; the route of administration; the renal and hepatic function of the patient; and the particular compound employed. Guidelines for pharmaceutical administration including pharmaceutical compositions are provided in, for example, *Remington's Pharmaceutical Sciences 18th Edition, supra.* and *Modern Pharmaceutics 2nd Edition, supra.*

Optimal precision in achieving concentrations of drug within the range that yields efficacy without toxicity requires a regimen based on the kinetics of the drug's availability to target sites. This involves a consideration of the distribution, equilibrium, and elimination of a drug. The daily dose for a patient is expected to be between 0.01 and 1,000 mg per adult patient per day.

EXAMPLES

Examples are provided below to further illustrate different features and advantages of the present invention. The examples also illustrate useful methodology for practicing the invention. These examples do not limit the claimed invention.

Example 1: MCH Receptor Related Sequences

Human MCH receptor related sequences are provided as follows:

5 Human MCH-R1 Nucleic Acid Sequence (SEQ. ID. NO. 1)

ATGGACCTGGAAGCCTCGCTGCTGCCCCACTGGTCCCAACGCCAGCAACAC
 CTCTGATGGCCCCGATAACCTCACTTCGGCAGGATCACCTCCTCGCACGG
 GGAGCATCTCCTACATCAACATCATCATGCCTTCGGTGTTTCGGCACCATCT
 GCCTCCTGGGCATCATCGGGAAGTCCACGGTCATCTTCGCGGTCGTGAAG
 10 AAGTCCAAGCTGCACTGGTGCAACAACGTCCCCGACATCTTCATCATCAA
 CCTCTCGGTAGTAGATCTCCTCTTTCTCCTGGGCATGCCCTTCATGATCCA
 CCAGCTCATGGGCAATGGGGTGTGGCACTTTGGGGAGACCATGTGCACCC
 TCATCACGGCCATGGATGCCAATAGTCAGTTCACCAGCACCTACATCCTG
 ACCGCCATGGCCATTGACCGCTACCTGGCCACTGTCCACCCCATCTCTTCC
 15 ACGAAGTTCCGGAAGCCCTCTGTGGCCACCCTGGTGATCTGCCTCCTGTGG
 GCCCTCTCCTTCATCAGCATCACCCCTGTGTGGCTGTATGCCAGACTCATC
 CCCTTCCCAGGAGGTGCAGTGGGCTGCGGCATACGCCTGCCCAACCCAGA
 CACTGACCTCTACTGGTTCACCCTGTACCAGTTTTTCCTGGCCTTTGCCCTG
 CCTTTTGTGGTCATCACAGCCGCATACGTGAGGATCCTGCAGCGCATGAC
 20 GTCCTCAGTGGCCCCCGCCTCCCAGCGCAGCATCCGGCTGCGGACAAAGA
 GGGTGACCCGCACAGCCATCGCCATCTGTCTGGTCTTCTTTGTGTGCTGGG
 CACCCTACTATGTGCTACAGCTGACCCAGTTGTCCATCAGCCGCCCCGACCC
 TCACCTTTGTCTACTTATACAATGCGGCCATCAGCTTGGGCTATGCCAACA
 GCTGCCTCAACCCCTTTGTGTACATCGTGCTCTGTGAGACGTTCCGCAAAC
 25 GCTTGGTCCTGTCGGTGAAGCCTGCAGCCCAGGGGCAGCTTCGCGCTGTC
 AGCAACGCTCAGACGGCTGACGAGGAGAGGACAGAAAGCAAAGGCACCT
 GA

Human MCH-R1 Amino Acid Sequence (SEQ. ID. NO. 2)

30 MDLEASLLPTGPNASNTSDGPDNLTSAGSPPTGSGISYINIIMPSVFGTICLLGIIG
 NSTVIFAVVKKSKLHWCNNVPDIFIINLSVVDLLFLLGMPFMIHQLMGNGVWH
 FGETMCTLITAMDANSQFTSTYILTAMADRYLATVHPISSTKFRKPSVATLVI
 CLLWALSFISITPVWLYARLIPFPGGAVGCGIRLPNPDTDLYWFTLYQFFLAFA
 LPFVVITAAYVRILQRMTSSVAPASQRSIRLRTKRVRTAIAICLVFFVCWAPY

YVLQLTQLSISRPTLTFVYLYNAAISLGYANSCLNPFVYIVLCETFRKRLVLSV
KPAAQGQLRAVSNAQTADEERTESKGT

Human MCH-R2 Nucleic Acid Sequence (SEQ. ID. NO. 3)

5 ATGAAGAAGGGAGTGGGGAGGGCAGTTGGGCTTGGAGGCGGCAGCGGCT
GCCAGGCTACGGAGGAAGACCCCCTTCCCAACTGCGGGGCTTGCCTCCG
GGACAAGGTGGCAGGCGCTGGAGGCTGCCGCAGCCTGCGTGGGTGGAGG
GGAGCTCAGCTCGGTTGTGGGAGCAGGCGACCGGCACTGGCTGGATGGAC
CTGGAAGCCTCGCTGCTGCCCACTGGTCCCAACGCCAGCAACACCTCTGA
10 TGGCCCCGATAACCTCACTTCGGCAGGATCACCTCCTCGCACGGGGAGCA
TCTCCTACATCAACATCATCATGCCTTCGGTGTTCGGCACCATCTGCCTCC
TGGGCATCATCGGGAACCTCCACGGTCATCTTCGCGGTCGTGAAGAAGTCC
AAGCTGCACTGGTGCAACAACGTCCCCGACATCTTCATCATCAACCTCTCG
GTAGTAGATCTCCTCTTTCTCCTGGGCATGCCCTTCATGATCCACCAGCTC
15 ATGGGCAATGGGGTGTGGCACTTTGGGGAGACCATGTGCACCCTCATCAC
GGCCATGGATGCCAATAGTCAGTTCACCAGCACCTACATCCTGACCGCCA
TGGCCATTGACCGCTACCTGGCCACTGTCCACCCCATCTCTTCCACGAAGT
TCCGGAAGCCCTCTGTGGCCACCCTGGTGATCTGCCTCCTGTGGGCCCTCT
CCTTCATCAGCATCACCCCTGTGTGGCTGTATGCCAGACTCATCCCTTCC
20 CAGGAGGTGCAGTGGGCTGCGGCATACGCCTGCCCAACCCAGACACTGAC
CTCTACTGGTTCACCCTGTACCAGTTTTTCCTGGCCTTTGCCCTGCCTTTTG
TGGTCATCACAGCCGCATACGTGAGGATCCTGCAGCGCATGACGTCCTCA
GTGGCCCCCGCCTCCCAGCGCAGCATCCGGCTGCGGACAAAGAGGGTGAC
CCGCACAGCCATCGCCATCTGTCTGGTCTTCTTTGTGTGCTGGGCACCCTA
25 CTATGTGCTACAGCTGACCCAGTTGTCCATCAGCCGCCCGACCCTCACCTT
TGTCTACTTATACAATGCGGCCATCAGCTTGGGCTATGCCAACAGCTGCCT
CAACCCCTTTGTGTACATCGTGCTCTGTGAGACGTTCCGCAAACGCTTGGT
CCTGTCCGTGAAGCCTGCAGCCCAGGGGCAGCTTCGCGCTGTCAGCAACG
CTCAGACGGCTGACGAGGAGAGGACAGAAAGCAAAGGCACCTGA

30

Human MCH-R2 Amino Acid Sequence (SEQ. ID. NO. 4)

MKKGVGRAVGLGGSGCQATEEDPLPNCGACAPGQGRRWRLPQPAWVEG
SSARLWEQATGTGWMDLEASLLPTGPNASNTSDGPDNLTSAGSPPRTSISYI
NIIMPSVFGTICLLGIIGNSTVIFAVVKKSKLHWCNNVPDIFIINLSVVDLLFLLG
35 MPFMIHQLMGNGVWHFGETMCTLITAMDANSQFTSTYILTAMAIIDRYLATVH

PISSTKFRKPSVATLVICLLWALSFISITPVWLYARLIPFPGGAVGCGIRLPNPD
 DLYWFTLYQFFLAFALPFVVITAA YVRILQRM TSSVAPASQRSIRLRTKRVTRT
 AIAICLVFFVCWAPYYVLQLTQLSISRPTLTFVYLYNAAISLGYANSCLNPFVYI
 VLCETFRKRLVLSVKPAAQGQLRAVSNAQTADERTESKGT

5

Human MCH-R3 Nucleic Acid Sequence (SEQ. ID. NO. 5)

ATGTCAGTGGGAGCCATGAAGAAGGGAGTGGGGAGGGCAGTTGGGCTTG
 GAGGCGGCAGCGGCTGCCAGGCTACGGAGGAAGACCCCCTTCCCAACTGC
 GGGGCTTGCGCTCCGGGACAAGGTGGCAGGCGCTGGAGGCTGCCGCAGC
 10 CTGCGTGGGTGGAGGGGAGCTCAGCTCGGTTGTGGGAGCAGGCGACCGG
 CACTGGCTGGATGGACCTGGAAGCCTCGCTGCTGCCCACTGGTCCCAACG
 CCAGCAACACCTCTGATGGCCCCGATAACCTCACTTCGGCAGGATCACCT
 CCTCGCACGGGGAGCATCTCCTACATCAACATCATCATGCCTTCGGTGTT
 GGCACCATCTGCCTCCTGGGCATCATCGGGAACCTCCACGGTCATCTTCGCG
 15 GTCGTGAAGAAGTCCAAGCTGCACTGGTGAACAACGTCCCCGACATCTT
 CATCATCAACCTCTCGGTAGTAGATCTCCTCTTTCTCCTGGGCATGCCCTT
 CATGATCCACCAGCTCATGGGCAATGGGGTGTGGCACTTTGGGGAGACCA
 TGTGCACCCTCATCACGGCCATGGATGCCAATAGTCAGTTCACCAGCACC
 TACATCCTGACCGCCATGGCCATTGACCGCTACCTGGCCACTGTCCACCCC
 20 ATCTCTTCCACGAAGTTCCGGAAGCCCTCTGTGGCCACCCTGGTGATCTGC
 CTCCTGTGGGCCCTCTCCTTCATCAGCATCACCCCTGTGTGGCTGTATGCC
 AGACTCATCCCCCTCCCAGGAGGTGCAGTGGGCTGCGGCATACGCCTGCC
 CAACCCAGACACTGACCTCTACTGGTTCACCCTGTACCAGTTTTTCCTGGC
 CTTTGCCCTGCCTTTTGTGGTCATCACAGCCGCATACGTGAGGATCCTGCA
 25 GCGCATGACGTCCTCAGTGGCCCCCGCCTCCCAGCGCAGCATCCGGCTGC
 GGACAAAGAGGGTGACCCGCACAGCCATCGCCATCTGTCTGGTCTTCTTT
 GTGTGCTGGGCACCCTACTATGTGCTACAGCTGACCCAGTTGTCCATCAGC
 CGCCCGACCCTCACCTTTGTCTACTTATAAATGCGGCCATCAGCTTGGGC
 TATGCCAACAGCTGCCTCAACCCCTTTGTGTACATCGTGCTCTGTGAGACG
 30 TTCCGCAAACGCTTGGTCCTGTCGGTGAAGCCTGCAGCCCAGGGGCAGCT
 TCGCGCTGTCAGCAACGCTCAGACGGCTGACGAGGAGAGGACAGAAAGC
 AAAGGCACCTGA

Human MCH-R3 Amino Acid Sequence (SEQ. ID. NO. 6)

MSVGAMKKGVGRAVGLGGSGCQATEEDPLPNCGACAPGQGRRWRLPQP
 AVEGSSARLWEQATGTGWMDLEASLLPTGPNASNTSDGPDNLTSA GSPPR
 TGSISYINIIMPSVFGTICLLGIIGNSTVIFAVVKKSKLHWCNNVPDIFIINLSVVD
 5 LLFLLGMPFMIHQLMGNGVWHFGETMCTLITAMDANSQFTSTYILTAMADR
 YLATVHPISSTKFRKPSVATLVICLLWALS FISITPVWLYARLIPFPGGAVGCGI
 RLPNPD TDLYWFTLYQFFLAFALPFVVITAAAYVRILQRM TSSVAPASQRSIRLR
 TKRVTRTAIAICLVFFVCWAPYYVLQLTQLSISRPTLTFVYLYNAAISLGYANS
 CLNPFVYIVLCETFRKRLVLSVKPAAQQLRAVSNAQTADEERTESKGT

10

SEQ. ID. NO. 7

ATGTCAGTGGGAGCCATGAAGAAGGGAGTGGGGAGGGCAGTTGGGCTTG
 GAGGCGGCAGCGGCTGCCAGGCTACGGAGGAAGACCCCTTCCCAACTGC
 GGGGCTTGCGCTCCGGGACAAGGTGGCAGGCGCTGGAGGCTGCCGCAGC
 15 CTGCGTGGGTGGAGGGGAGCTCAGCTCGGTTGTGGGAGCAGGCGACCGG
 CACTGGCTGG

SEQ. ID. NO. 8

MSVGAMKKGVGRAVGLGGSGCQATEEDPLPNCGACAPGQGRRWRLPQP
 20 AVEGSSARLWEQATGTGW

MCH-R3 DNA with Intron (lower case) SEQ. ID. NO. 9

ATGTCAGTGGGAGCCATGAAGAAGGGAGTGGGGAGGGCAGTTGGGCTTG
 GAGGCGGCAGCGGCTGCCAGGCTACGGAGGAAGACCCCTTCCCAACTGC
 25 GGGGCTTGCGCTCCGGGACAAGGTGGCAGGCGCTGGAGGCTGCCGCAGC
 CTGCGTGGGTGGAGGGGAGCTCAGCTCGGTTGTGGGAGCAGGCGACCGG
 CACTGGCTGGATGGACCTGGAAGCCTCGCTGCTGCCCACTGGTCCCAACG
 CCAGCAACACCTCTGATGGCCCCGATAACCTCACTTCGGCAGgtgagttgactggg
 agccctccctcctctgggctgtgggtggaaaatgggaaggttcacccctgagccaaactgcttgggaaactttatcacagt
 30 cttggggacaagatctgtgtctgctttgctctgaggggcaggagaaaagggggcaatggtccgcaggggcagacgggc
 aggagcagagcagggggcggaaggcatattcagaatggcaaggaagggggccagccgtgagacagcagggggaaggc
 tcgctgctgggttccaaagatgcttggcagaaaaattccaggctggaaaagcaagcgagagaagctggagggtggtatg
 gggagacagctgggggctcactcctgcactgttagcctcagcttttactcccacttggatgatgaggtctgagacatcctac
 tgccacctgggagaggccctgggaagggaagacttcacagagccatgaggggattaactttctggtgaattaagcttctg
 35 acatttcagagctgcggtgccctgggattccagcttgaaggagaaaggaaggaaaggaaaaggaaaggcttatgtag

ataattttccaggctgctgagctccaacagacagtttctgtctctgcttcaagaagcccaggctcagaagataccaatc
 aaggaaatccccgctaggaagcctggggtagggagagctgctggcttgaccagggcacagccggcaaaagcctctacaa
 gacagtcacccacagatatgccaagaatcgtacacagtttccaaccagagatctccaaaatgaaacactcagggtaca
 cataggaaaagcacgcacacacacacacacacacacacagacacttactttgtgtccttctggctatgctgacgagtttc
 5 ctggtgaagcccggtcacagagtaatctctgcagacaactgtggttcttgctctggtgcctgcaggaggcaggcatgt
 tgtgtcctccaagacagatggctcagggcactctggtaggattcaccaggaaactcatggagaagggaagggacaag
 attagcaacagtgaaggaggaggagaatggtgggagaggattccagatgaacgggtgggtcgtggagggtgagcatgcca
 gcaggatgtcagttctcagagcaaaagcccatgtcaaacagccaacgcttgctccttctgtccccagGATCACCTCC
 TCGCACGGGGAGCATCTCCTACATCAACATCATCATGCCTTCGGTGTTCGG
 10 CACCATCTGCCTCCTGGGCATCATCGGGAACCTCCACGGTCATCTTCGCGGT
 CGTGAAGAAGTCCAAGCTGCACTGGTGCAACAACGTCCCCGACATCTTCA
 TCATCAACCTCTCGGTAGTAGATCTCCTCTTTCTCCTGGGCATGCCCTTCAT
 GATCCACCAGCTCATGGGCAATGGGGTGTGGCACTTTGGGGAGACCATGT
 GCACCCTCATCACGGCCATGGATGCCAATAGTCAGTTCACCAGCACCTAC
 15 ATCCTGACCGCCATGGCCATTGACCGCTACCTGGCCACTGTCCACCCCATC
 TCTTCCACGAAGTCCGGAAGCCCTCTGTGGCCACCCTGGTGATCTGCCTC
 CTGTGGGCCCTCTCCTTCATCAGCATCACCCCTGTGTGGCTGTATGCCAGA
 CTCATCCCCCTTCCCAGGAGGTGCAGTGGGCTGCGGCATACGCCTGCCCAA
 CCCAGACACTGACCTCTACTGGTTCACCCTGTACCAGTTTTTCTCCTGGCCTT
 20 TGCCCTGCCTTTTGTGGTCATCACAGCCGCATACGTGAGGATCCTGCAGCG
 CATGACGTCCTCAGTGGCCCCCGCCTCCCAGCGCAGCATCCGGCTGCGGA
 CAAAGAGGGTGACCCGCACAGCCATCGCCATCTGTCTGGTCTTCTTTGTGT
 GCTGGGCACCCTACTATGTGCTACAGCTGACCCAGTTGTCCATCAGCCGCC
 CGACCCTCACCTTTGTCTACTTATACAATGCGGCCATCAGCTTGGGCTATG
 25 CCAACAGCTGCCTCAACCCCTTTGTGTACATCGTGCTCTGTGAGACGTTCC
 GCAAACGCTTGGTCCTGTGCGGTGAAGCCTGCAGCCCAGGGGCAGCTTCGC
 GCTGTGACGCAACGCTCAGACGGCTGACGAGGAGAGGACAGAAAGCAAAG
 GCACCTGA

30 Example 2: Melanophore Assay For Determination
 Of G protein-Coupled Receptor Activation

35 Melanophores were transfected with either a vector designed to
 synthesize SLC-1 mRNA and thereby lead to overexpression of SLC-1 receptor (*i.e.*,
 pcDNA3-hSLC-1), the empty vector (pcDNA3), and plasmids encoding control

receptors (*i.e.*, pcDNA1amp-CB2 and pcDNA3-thromboxane A2). The plasmid vector pcDNA3 (Invitrogen) was used to express the recombinant SLC-1 mRNA and protein in cells transfected with this construct. The coding sequence of the SLC-1 cDNA without its untranslated 5' and 3' sequences (SEQ. ID. NO. 1) was subcloned by blunt-end ligation into the EcoRV site of pcDNA3. The SLC-1 cDNA insert can be excised from pcDNA3-hSLC-1 by restriction digestion of the plasmid with KpnI and XbaI. The amino-terminal coding end of the SLC-1 insert was cloned proximal to the Cytomegalovirus promoter contained in pcDNA3. The carboxyl-terminal coding sequences of the SLC-1 insert was cloned proximal to the bovine growth hormone polyadenylation signal sequence in pcDNA3.

Growth of *Xenopus laevis* melanophores and fibroblasts was performed as described previously (Daniolos, *et al.*, 1992. *Pigment Cell Res.* 3, 38-43; and Lerner, 1994. *Trends Neurol. Sci.* 17, 142-146). Briefly, melanophores were grown in *Xenopus* fibroblast-conditioned growth medium. The fibroblast-conditioned growth medium was prepared by growing *Xenopus* fibroblasts in 70% L-15 medium (Sigma), pH 7.3, supplemented with 20 % heat inactivated fetal bovine serum (Life Technologies, Mississauga, Ont), 100 µg/ml streptomycin, 100 units/ml penicillin and 2 mM glutamine at 27°C. The medium from growing fibroblasts was collected, passed through a 0.2 micron filter (referred to as fibroblast-conditioned growth medium) and used to culture melanophores at 27°C. Plasmid DNA was transiently transfected into melanophores by electroporation using a BTX ECM600 electroporator (Genetronics, Inc. San Diego, CA).

Melanophores were incubated in the presence of fresh fibroblast-conditioned growth medium for 1 hour prior to harvesting of cells. Melanophore monolayers were detached by trypsinization (0.25% trypsin, JHR Biosciences, Lenexa, KS), followed by inactivation of the trypsin with fibroblast-conditioned growth medium.

The cells were collected by centrifugation at 200 x g for 5 minutes at 4°C. Cells were washed once in fibroblast conditioned growth medium, centrifuged (200 x g, 5 minutes, 4°C) and resuspended at 5×10^6 cells per ml in ice cold 70% PBS pH 7.0. 400 µl aliquots of cells in PBS were added to prechilled 1.5 ml tubes containing 2 µg of pcDNA3-hSLC-1 plasmid DNA, 2 µg each of two internal control GPCRs (pcDNA1amp-cannabinoid 2 and pcDNA3-thromboxane A2; Slipitz, *et al.*, 1995. *Mol. Pharmacol.* 48, 352-361), and 18 µg of pcDNA3.1 plasmid vector DNA

for a total of 24 μ g DNA in a 40 μ l total volume. Samples were incubated on ice for 20 minutes with mixing every 7 minutes.

Cell and DNA mixes were transferred to prechilled 0.2 mm gap electroporation cuvettes (BTX) and electroporated using the following settings: capacitance of 325 microfarad, voltage of 450 volts and resistance of 720 ohms. Immediately following electroporation, cells were mixed with fibroblast-conditioned growth medium and plated onto flat bottom 96 well microtiter plates (NUNC). Electroporations from multiple cuvettes were pooled together prior to plating to ensure homogenous transfection efficiency.

On the day following transfection, the media was replaced with fresh fibroblast-conditioned growth media and incubated for one to three days at 27°C prior to assaying for receptor expression. On the day of ligand stimulation, medium was removed by aspiration and cells were washed with 70% L-15 media containing 15 mM HEPES, pH 7.3.

Assays were divided into two separate parts in order to examine Gs/Gq-coupling which results in pigment dispersion in melanophores, or Gi-coupling which results in pigment aggregation. For Gs/Gq-coupling responses, assays were performed as follows. Cells were incubated in 100 μ l of 70% L-15 media containing 15 mM HEPES, pH 7.3, for 1 hour in the dark at room temperature, and then incubated in the presence of melatonin (2 nM final concentration) for 1 hour in the dark at room temperature to induce pigment aggregation. Initial absorbance readings at 600 nm were measured using a Bio-Tek Elx800 Microplate reader (ESBE Scientific) prior to addition of ligand. Ligands (100 nM final concentration in DMSO for small molecules non-peptides or 150 nM final concentration in 0.1N acetic acid for peptide molecules) were added to wells, mixed, and incubated in the dark at room temperature for 1 hour, after which the final absorbance at 600 nm was determined.

For Gi-coupled responses, cell monolayers plated in 96-well microtiter plates were incubated in the presence of 100 μ l/well of 70% L-15 media containing 2% fibroblast-conditioned growth medium, 2 mM glutamine, 100 μ g/ml streptomycin, 100 units/ml penicillin and 15 mM HEPES, pH 7.3, for 15 minutes in the dark at room temperature to preset the cells to dispersion. Initial absorbance readings at 600 nm were determined, followed by the addition of ligands. After a 1.5 hour incubation in the dark at room temperature final absorbances were determined. Absorbance readings were converted to transmission values to quantitate pigment

dispersion using the following formula: $1 - T_f/T_i$, where T_i = the initial transmission at 600 nm and T_f = the final transmission at 600 nm.

Example 3: MCH-R1 Receptor Activity

5

The *Xenopus* melanophore system (Daniolos, *et al.*, 1992. *Pigment Cell Res.* 3, 38-43) is based on the dispersion and aggregation of intracellular pigment granules in response to changes in intracellular second messenger molecules. Agonist activation of a recombinant Gs- or Gq-coupled receptor expressed heterologously in melanophores leads to pigment dispersion. Conversely, agonist activation of a recombinant Gi-coupled receptor expressed heterologously in melanophores leads to pigment aggregation. Changes in the melanophore pigmentation show a dose-dependent correlation with the level of specific receptor activation, and can be quantified by the change in absorbance at 600 nm between the nonactivated and agonist-activated cells (Daniolos, *et al.*, 1992. *Pigment Cell Res.* 3, 38-43).

15

Melanophores transiently transfected with plasmid DNAs expressing "SLC-1", cannabinoid 2 and thromboxane A2 receptors were plated onto 96 well microtiter plates. Following the above pretreatment conditions, cells were incubated for 1 hour in the presence of a collection of 202 known small molecules and peptides including MCH. The test ligand collection included 80 small molecules (a different test molecule in each well) at 100 nM final concentration, 80 peptides at 150 nM final concentration and 42 small molecules and peptides at 500 and 1000 nM final concentration, respectively.

20

Pigment aggregation responses (Gi-coupled responses) were detected with the following five peptides from the peptide plate (150 nM final concentration): thrombin, MCH, valosin, RANTES and CGRP with responses ranging from 33% to 66% of the positive cannabinoid 2 receptor control activated by the cannabinoid receptor agonist, HU-210. Background aggregation responses in this assay range from 0 – 25% of the positive control cannabinoid 2 receptor response. The response seen for thrombin is detected in mock (non-receptor) transfected melanophores and represents activation of the endogenous melanophore thrombin receptor. Other controls include a positive aggregation response to melatonin, stimulating the endogenous *Xenopus* receptor and a lack of aggregation response to PBS, acetic acid or DMSO vehicle controls (15%, 11% and 3% of the positive cannabinoid 2 receptor positive control value, respectively).

25

30

35

Example 4: MCH Receptor Binding Assay

5 The MCH receptor binding assay can be conducted on cells transfected
with a MCH-R2 expression plasmid (full-length open reading frame of SEQ. ID. NO.
5 placed in the mammalian expression vector pcDNA-3 (Invitrogen, Carlsbad, CA) or
a MCH-R2 expression plasmid (full-length open reading frame of SEQ. ID. NO. 3
placed in the mammalian expression vector pcDNA-3 (Invitrogen, Carlsbad, CA) to
produce a MCH-R expression plasmid. Mammalian cells HEK-293 or COS-7 are
10 transfected with vector using Lipofectamine (GIBCO-BRL; Hawley-Nelson, P. 1993,
Focus 15:73). Transfections are performed in 60 mm dishes on 80% confluent cells
(approximately 4×10^5 cells) with 8 μ g of Lipofectamine and 32 μ g of MCH-R
plasmid DNA.

Binding of [125 I]-MCH is measured using crude membranes prepared
15 from HEK-293 or COS-7 cells transfected with MCH-R expression plasmids. Crude
cell membranes from COS-7 or HEK-293 transfectants are prepared on ice, 48 hours
post-transfection. Each 60 mm dish is washed twice with 3 ml of PBS, once with 1
ml homogenization buffer (50 mM Tris-HCl [pH 7.4], 5 mM MgCl_2 , 2.5 mM EDTA,
30 μ g/ml bacitracin, 1 μ M phosphoramidon, 0.2 % BSA). 0.5 ml of homogenization
buffer is added to each dish, cells are removed by scraping and then homogenized
using a Polytron device (Brinkmann, Syosset, NY; 3 bursts of 10 sec. at setting 4).
The homogenate is then centrifuged for 20 minutes at 11,000 x g at 0°C and the
resulting crude membrane pellet (chiefly containing cell membranes and nuclei) is
resuspended in homogenization buffer supplemented with 0.06% BSA (0.1 ml/60 mm
25 dish) and kept on ice.

Binding reactions are performed at 20°C for 1 hour in a total volume of
0.5 ml containing: 0.1 ml of membrane suspension, 10 μ l of [125 I]-MCH (0.05 to 1
nM; specific activity approximately 2000 Ci/mmol), 10 μ l of competing compound(s)
and 380-390 μ l of homogenization buffer. Bound radioligand is separated by rapid
30 vacuum filtration (Brandel 48-well cell harvester) through GF/C filters pretreated for
1 hour with 0.5% polyethylenimine. After application of the membrane suspension to
the filter, the filters are washed 3 times with 3 ml each of ice cold 50 mM Tris-HCl
[pH 7.4], 10 mM MgCl_2 , 2.5 mM EDTA and 0.015% Triton X-100, and the bound
radioactivity on the filters is quantitated by gamma counting. Specific binding (> 90%

of total) is defined as the difference between total binding and non-specific binding conducted in the presence of 100 nM unlabeled MCH.

- Other embodiments are within the following claims. While several embodiments have been shown and described, various modifications may be made without departing from the spirit and scope of the present invention.
- 5

WHAT IS CLAIMED IS:

1. A purified nucleic acid comprising a nucleotide sequence encoding for at least 5 contiguous amino acids of SEQ. ID. NO. 8.
2. The nucleic acid of claim 1, wherein said nucleotide sequence encodes for amino acids 1-5 of SEQ. ID. NO. 8.
3. The nucleic acid of claim 1, wherein said nucleotide sequence encodes for at least 9 contiguous amino acids of SEQ. ID. NO. 8.
4. The nucleic acid of claim 1, wherein said nucleic acid comprises at least about 18 contiguous nucleotides of SEQ. ID. NO. 7.
5. The nucleic acid of claim 1, wherein said nucleic acid comprises the nucleotide sequence of SEQ. ID. NO. 3.
6. The nucleic acid of claim 1, wherein said nucleotide sequence encodes for the amino acid sequence of SEQ. ID. NO. 4.
7. The nucleic acid of claim 1, wherein said nucleic acid comprises the nucleotide sequence of SEQ. ID. NO. 5.
8. The nucleic acid of claim 1, wherein said nucleotide sequence encodes for the amino acid sequence of SEQ. ID. NO. 6.
9. An expression vector comprising a nucleotide sequence encoding for a polypeptide comprising at least 5 contiguous amino acids of SEQ. ID. NO. 8.
10. The expression vector of claim 9, wherein said nucleotide sequence is functionally coupled to an exogenous promoter.
11. The expression vector of claim 10, wherein said nucleotide sequence encodes for at least 9 contiguous amino acids of SEQ. ID. NO. 8.

12. The expression vector of claim 10, wherein said expression vector comprises the nucleotide sequence of SEQ. ID. NO. 3.

5 13. The expression vector of claim 10, wherein said nucleotide sequence encodes the amino acid sequence of SEQ. ID. NO. 4.

14. The expression vector of claim 10, wherein said expression vector comprises the nucleotide sequence of SEQ. ID. NO. 5.

10 15. The expression vector of claim 10, wherein said nucleotide sequence encodes the amino acid sequence of SEQ. ID. NO. 6.

15 16. A recombinant cell comprising the expression vector of claim 9.

17. A method of preparing a MCH receptor polypeptide comprising the step of growing the recombinant cell of claim 16 under conditions wherein said polypeptide is expressed from said expression vector.

20 18. A purified nucleic acid comprising a region of 20 contiguous nucleotides, wherein at least 16 nucleotides present in said region hybridize to a complementary region of 20 contiguous nucleotides present in SEQ. ID. NO. 7 or the complement thereof.

25 19. A polypeptide comprising an amino acid sequence encoding for at least about 9 contiguous amino acids of SEQ. ID. NO. 8, wherein said polypeptide is substantially free of associated proteins.

30 20. The polypeptide of claim 19, wherein said polypeptide comprises the amino acid sequence of SEQ. ID. NO. 4.

35 21. The polypeptide of claim 19, wherein said polypeptide comprises the nucleotide sequence of SEQ. ID. NO. 6.

22. A method for screening for a compound able to bind a MCH receptor comprising the steps of:

(a) expressing a polypeptide comprising the amino acid sequence of SEQ. ID. NO. 4, SEQ. ID. NO. 6, or a fragment thereof, from recombinant nucleic acid, provided that said fragment comprises at least about 9 contiguous amino acids of SEQ. ID. NO. 8;

(b) providing to said polypeptide a test preparation comprising one or more test compounds; and

(c) measuring the ability of said test preparation to bind to said polypeptide.

23. The method of claim 22, wherein said steps (b) and (c) are performed *in vitro*.

24. The method of claim 22, wherein said steps (a), (b) and (c) are performed using a whole cell.

25. The method of claim 22, wherein said polypeptide is expressed from an expression vector.

26. The method of claim 25, wherein said polypeptide comprises the amino acid sequence of SEQ. ID. NO. 6.

27. The method of claim 25, wherein said step (b) further comprises the presence of labeled MCH, and said step (c) measures the ability of said test preparation to inhibit binding of said labeled MCH to said polypeptide.

28. A method for screening for a compound able to modulate MCH receptor activity comprising the steps of:

(a) contacting a cell line expressing recombinant nucleic acid encoding for a MCH receptor comprising the amino acid sequence of SEQ. ID. NO. 4 or 6 with a test preparation comprising one or more test compounds; and

(b) measuring the effect of said test preparation on the activity of said receptor.

29. The method of claim 28, wherein said MCH receptor comprises the amino acid sequence of SEQ. ID. NO. 4.

5 30. The method of claim 28, wherein said MCH receptor consists of the amino acid sequence of SEQ. ID. NO. 6.

31. The method of claim 30, wherein said method further comprises the presence of an MCH receptor agonist.

10 32. A method for suppressing appetite comprising the step of administering to a patient an effective amount of means for decreasing MCH receptor expression targeting a nucleic acid region within SEQ. ID. NO. 7.

15 33. The method of claim 32, wherein said means is enzymatic nucleic acid or antisense nucleic acid.

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:	Howard, Andrew D.		
Serial No.:	TBA	Case No.:	20493P
Filed:	January 10, 2002		
For:	MELANIN-CONCENTRATING HORMONE RECEPTOR		
Art Unit:			
Examiner:			

Assistant Commissioner for Patents
Washington, D.C. 20231

SEQUENCE LISTING STATEMENT

Sir:

The contents of the enclosed paper and computer readable copies of the Sequence Listing, submitted in accordance with 37 C.F.R. §1.821 *et seq*, are the same.

No fee is believed to be due. However, the Commissioner is authorized to charge Deposit Account No. 13-2755 for any amount necessary for the entry of this Sequence Listing.

EXPRESS MAIL CERTIFICATE
DATE OF DEPOSIT 1-10-2002
EXPRESS MAIL NO. EM230307798US
I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS
BEING DEPOSITED WITH THE UNITED STATES POSTAL
SERVICE AS EXPRESS MAIL "POST OFFICE TO
ADDRESSEE" BEFORE 5 P.M. ON THE ABOVE DATE IN
AN ENVELOPE ADDRESSED TO ASSISTANT COMMISSIONER
FOR PATENTS, WASHINGTON, D.C., 20231
MAILED BY S. B. Crowley
1/10/02

Date: January 10, 2002

Respectfully submitted,

By Sh O Heber
Sheldon O. Heber
Reg. No. 38,179
Attorney for Applicants
Merck & Co., Inc.
P.O. Box 2000 - RY60-30
Rahway, NJ 07065-0907
(732) 594-1958

10/031014

531 Rec'd PCT/F 10 JAN 2002

SEQUENCE LISTING

<110> Merck & Co., Inc.

<120> Melanin-Concentrating Hormone Receptor

<130> 20493 PCT

<150> US 60/143,706

<151> 1999-07-14

<160> 10

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 1062

<212> DNA

<213> Human

<400> 1

atggacctgg	aagcctcgct	gctgcccact	ggtcccaacg	ccagcaaacac	ctctgatggc	60
cccgataaac	tcacttcggc	aggatcacct	cctcgcacgg	ggagcatctc	ctacatcaac	120
atcatcatgc	cttcggtggt	cggcaccatc	tgctctctgg	gcatcatcgg	gaactccacg	180
gtcatcttcg	cggtcgtgaa	gaagtccaag	ctgcactggg	gcaacaacgt	ccccgacatc	240
ttcatcatca	acctctcggt	agtagatctc	ctctttctcc	tgggcatgcc	cttcatgatc	300
caccagctca	tgggcaatgg	ggtgtggcac	tttggggaga	ccatgtgcac	cctcatcacg	360
gccatggatg	ccaatagtca	gttcaccagc	acctacatcc	tgaccgccat	ggccattgac	420
cgctacctgg	ccactgtcca	ccccatctct	tccacgaagt	tccggaagcc	ctctgtggcc	480
accctgggtga	tctgctctct	gtggggccctc	tccttcatca	gcatcacccc	tgtgtggctg	540
tatgccagac	tcattcccctt	cccaggaggt	gcagtgggct	gcggcatacg	cctgcccac	600
ccagacactg	acctctactg	gttcaccctg	taccagtttt	tcctggcctt	tgccctgcct	660
tttgtgggtca	tcacagccgc	atacgtgagg	atcctgcagc	gcatgacgtc	ctcagtggcc	720
ccgcctccc	agcgcagcat	cgggtgcgg	acaaagaggg	tgaccgcgac	agccatcgcc	780
atctgtcttg	tcttctttgt	gtgctgggca	ccctactatg	tgctacagct	gacccagttg	840
tccatcagcc	gcccgaacct	cacctttgtc	tacttatata	atgcggccat	cagcttgggc	900
tatgccaaca	gctgcctcaa	cccctttgtg	tacatcgtgc	tctgtgagac	gttccgcaaa	960
cgcttggtcc	tgctcggtgaa	gcctgcagcc	caggggcagc	ttcgcgctgt	cagcaacgct	1020
cagacggctg	acgaggagag	gacagaaagc	aaaggcacct	ga		1062

<210> 2

<211> 353

<212> PRT

<213> Human

<400> 2

Met	Asp	Leu	Glu	Ala	Ser	Leu	Leu	Pro	Thr	Gly	Pro	Asn	Ala	Ser	Asn
1				5					10					15	
Thr	Ser	Asp	Gly	Pro	Asp	Asn	Leu	Thr	Ser	Ala	Gly	Ser	Pro	Pro	Arg
			20					25					30		
Thr	Gly	Ser	Ile	Ser	Tyr	Ile	Asn	Ile	Ile	Met	Pro	Ser	Val	Phe	Gly
		35				40					45				
Thr	Ile	Cys	Leu	Leu	Gly	Ile	Ile	Gly	Asn	Ser	Thr	Val	Ile	Phe	Ala
	50				55				60						
Val	Val	Lys	Lys	Ser	Lys	Leu	His	Trp	Cys	Asn	Asn	Val	Pro	Asp	Ile
65				70					75					80	
Phe	Ile	Ile	Asn	Leu	Ser	Val	Val	Asp	Leu	Leu	Phe	Leu	Leu	Gly	Met
			85					90						95	
Pro	Phe	Met	Ile	His	Gln	Leu	Met	Gly	Asn	Gly	Val	Trp	His	Phe	Gly
			100					105						110	

2007-10-14 10:10:00

Glu Thr Met Cys Thr Leu Ile Thr Ala Met Asp Ala Asn Ser Gln Phe
 115 120 125
 Thr Ser Thr Tyr Ile Leu Thr Ala Met Ala Ile Asp Arg Tyr Leu Ala
 130 135 140
 Thr Val His Pro Ile Ser Thr Lys Phe Arg Lys Pro Ser Val Ala
 145 150 155 160
 Thr Leu Val Ile Cys Leu Leu Trp Ala Leu Ser Phe Ile Ser Ile Thr
 165 170 175
 Pro Val Trp Leu Tyr Ala Arg Leu Ile Pro Phe Pro Gly Gly Ala Val
 180 185 190
 Gly Cys Gly Ile Arg Leu Pro Asn Pro Asp Thr Asp Leu Tyr Trp Phe
 195 200 205
 Thr Leu Tyr Gln Phe Phe Leu Ala Phe Ala Leu Pro Phe Val Val Ile
 210 215 220
 Thr Ala Ala Tyr Val Arg Ile Leu Gln Arg Met Thr Ser Ser Val Ala
 225 230 235 240
 Pro Ala Ser Gln Arg Ser Ile Arg Leu Arg Thr Lys Arg Val Thr Arg
 245 250 255
 Thr Ala Ile Ala Ile Cys Leu Val Phe Phe Val Cys Trp Ala Pro Tyr
 260 265 270
 Tyr Val Leu Gln Leu Thr Gln Leu Ser Ile Ser Arg Pro Thr Leu Thr
 275 280 285
 Phe Val Tyr Leu Tyr Asn Ala Ala Ile Ser Leu Gly Tyr Ala Asn Ser
 290 295 300
 Cys Leu Asn Pro Phe Val Tyr Ile Val Leu Cys Glu Thr Phe Arg Lys
 305 310 315 320
 Arg Leu Val Leu Ser Val Lys Pro Ala Ala Gln Gly Gln Leu Arg Ala
 325 330 335
 Val Ser Asn Ala Gln Thr Ala Asp Glu Glu Arg Thr Glu Ser Lys Gly
 340 345 350
 Thr

<210> 3
 <211> 1254
 <212> DNA
 <213> Human

<400> 3
 atgaagaagg gagtggggag ggcagttggg cttggaggcg gcagcggctg ccaggctacy 60
 gaggaagacc cccttcccaa ctgcggggct tgcgctccgg gacaagggtg caggcgctgg 120
 aggctgccgc agcctgcgtg ggtggagggg agctcagctc ggttggtgga gcaggcgacc 180
 ggcactggct ggatggacct ggaagcctcg ctgctgccca ctggtcccaa cgccagcaac 240
 acctctgatg gccccgataa cctcacttcg gcaggatcac ctccctcgac ggggagcatc 300
 tcctacatca acatcatcat gccttcggtg ttcggcacca tctgcctcct gggcatcatc 360
 gggaactcca cggatcatct cgcggtcggt aagaagtcca agctgcactg gtgcaacaac 420
 gtccccgaca tcttcatcat caacctctcg gtatgagatc tcctctttct cctgggcatg 480
 cccttcatga tccaccagct catgggcaat ggggtgtggc actttgggga gaccatgtgc 540
 accctcatca cggccatgga tgccaatagt cagttcacca gcacctacat cctgaccgcc 600
 atggccattg accgctacct ggccactgtc caccctatct cttccacgaa gttccggaag 660
 ccctctgtgg ccaccctggt gatctgcctc ctgtggggccc tctccttcat cagcatcacc 720
 cctgtgtggc tgtatgccag actcatcccc ttcccaggag gtgcagtggg ctgcggcata 780
 cgctgcccc acccagacac tgacctctac tggttcaccc tgtaccagtt ttctctggcc 840
 tttgccctgc cttttgtggt catcacagcc gcatacgtga ggatccctgca gcgcatgacg 900
 tcctcagtgg cccccgcctc ccagcgcagc atccggctgc ggacaaagag ggtgaccgcg 960
 acagccatcg ccattctgtc ggtcttcttt gtgtgctggg caccctacta tgtgctacag 1020
 ctgacccagt tgtccatcag ccgcccagacc ctcacctttg tctacttata caatgcggcc 1080
 atcagcttgg gctatgcaa cagctgcctc aaccctttg tgtacatcgt gctctgtgag 1140
 acgttccgca aacgcttggc cctgtcggtg aagcctgcag cccaggggca gcttcgcgct 1200
 gtcagcaacg ctcagacggc tgacgaggag aggacagaaa gcaaaggcac ctga 1254

<210> 4

<211> 417
 <212> PRT
 <213> Human

<400> 4

Met	Lys	Lys	Gly	Val	Gly	Arg	Ala	Val	Gly	Leu	Gly	Gly	Gly	Ser	Gly
1				5					10					15	
Cys	Gln	Ala	Thr	Glu	Glu	Asp	Pro	Leu	Pro	Asn	Cys	Gly	Ala	Cys	Ala
			20					25					30		
Pro	Gly	Gln	Gly	Gly	Arg	Arg	Trp	Arg	Leu	Pro	Gln	Pro	Ala	Trp	Val
		35					40					45			
Glu	Gly	Ser	Ser	Ala	Arg	Leu	Trp	Glu	Gln	Ala	Thr	Gly	Thr	Gly	Trp
	50				55						60				
Met	Asp	Leu	Glu	Ala	Ser	Leu	Leu	Pro	Thr	Gly	Pro	Asn	Ala	Ser	Asn
65					70					75					80
Thr	Ser	Asp	Gly	Pro	Asp	Asn	Leu	Thr	Ser	Ala	Gly	Ser	Pro	Pro	Arg
			85						90				95		
Thr	Gly	Ser	Ile	Ser	Tyr	Ile	Asn	Ile	Ile	Met	Pro	Ser	Val	Phe	Gly
			100					105					110		
Thr	Ile	Cys	Leu	Leu	Gly	Ile	Ile	Gly	Asn	Ser	Thr	Val	Ile	Phe	Ala
		115					120					125			
Val	Val	Lys	Lys	Ser	Lys	Leu	His	Trp	Cys	Asn	Asn	Val	Pro	Asp	Ile
	130					135					140				
Phe	Ile	Ile	Asn	Leu	Ser	Val	Val	Asp	Leu	Leu	Phe	Leu	Leu	Gly	Met
145					150				155						160
Pro	Phe	Met	Ile	His	Gln	Leu	Met	Gly	Asn	Gly	Val	Trp	His	Phe	Gly
			165					170					175		
Glu	Thr	Met	Cys	Thr	Leu	Ile	Thr	Ala	Met	Asp	Ala	Asn	Ser	Gln	Phe
			180					185					190		
Thr	Ser	Thr	Tyr	Ile	Leu	Thr	Ala	Met	Ala	Ile	Asp	Arg	Tyr	Leu	Ala
		195					200					205			
Thr	Val	His	Pro	Ile	Ser	Ser	Thr	Lys	Phe	Arg	Lys	Pro	Ser	Val	Ala
		210				215					220				
Thr	Leu	Val	Ile	Cys	Leu	Leu	Trp	Ala	Leu	Ser	Phe	Ile	Ser	Ile	Thr
225					230					235					240
Pro	Val	Trp	Leu	Tyr	Ala	Arg	Leu	Ile	Pro	Phe	Pro	Gly	Gly	Ala	Val
			245						250					255	
Gly	Cys	Gly	Ile	Arg	Leu	Pro	Asn	Pro	Asp	Thr	Asp	Leu	Tyr	Trp	Phe
			260					265					270		
Thr	Leu	Tyr	Gln	Phe	Phe	Leu	Ala	Phe	Ala	Leu	Pro	Phe	Val	Val	Ile
		275					280					285			
Thr	Ala	Ala	Tyr	Val	Arg	Ile	Leu	Gln	Arg	Met	Thr	Ser	Ser	Val	Ala
		290				295					300				
Pro	Ala	Ser	Gln	Arg	Ser	Ile	Arg	Leu	Arg	Thr	Lys	Arg	Val	Thr	Arg
305					310					315					320
Thr	Ala	Ile	Ala	Ile	Cys	Leu	Val	Phe	Phe	Val	Cys	Trp	Ala	Pro	Tyr
			325					330						335	
Tyr	Val	Leu	Gln	Leu	Thr	Gln	Leu	Ser	Ile	Ser	Arg	Pro	Thr	Leu	Thr
			340				345						350		
Phe	Val	Tyr	Leu	Tyr	Asn	Ala	Ala	Ile	Ser	Leu	Gly	Tyr	Ala	Asn	Ser
		355				360						365			
Cys	Leu	Asn	Pro	Phe	Val	Tyr	Ile	Val	Leu	Cys	Glu	Thr	Phe	Arg	Lys
	370					375					380				
Arg	Leu	Val	Leu	Ser	Val	Lys	Pro	Ala	Ala	Gln	Gly	Gln	Leu	Arg	Ala
385					390					395					400
Val	Ser	Asn	Ala	Gln	Thr	Ala	Asp	Glu	Glu	Arg	Thr	Glu	Ser	Lys	Gly
				405					410					415	

Thr

<210> 5
 <211> 1269

<212> DNA
<213> Human

<400> 5
 atgtcagttg gagccatgaa gaagggagtg gggagggcag ttgggcttgg aggcggcagc 60
 ggctgccagg ctacggagga agacccctt cccaactgcg gggcttgcg tccgggacaa 120
 ggtggcaggc gctggaggct gccgcagcct gcgtgggtgg aggggagctc agctcgggtg 180
 tgggagcagg cgaccggcac tggctggatg gacctggaag cctcgctgct gcccactggg 240
 cccaacgcca gcaacacctc tgatggcccc gataacctca cttcggcagg atcacctcct 300
 cgcacgggga gcatctccta catcaacatc atcatgcctt cgggtgtcgg caccatctgc 360
 ctctcgggca tcatcgggaa ctccacggtc atcttcgcgg tcgtgaagaa gtccaagctg 420
 cactggtgca acaacgtccc cgacatcttc atcatcaacc tctcggtagt agatctcctc 480
 tttctcctgg gcatgccctt catgatccac cagctcatgg gcaatggggg gtggcacttt 540
 ggggagacca tgtgcaccct catcacggcc atggatgcca atagtcagtt caccagcacc 600
 tacatcctga ccgccatggc cattgaccgc tacctggcca ctgtccaccc catctcttcc 660
 acgaagttcc ggaagccctc tgtggccacc ctggtgatct gcctcctgtg ggccctctcc 720
 ttcacagca tcacccctgt gtggctgtat gccagactca tccccttccc aggaggtgca 780
 gtgggctgcg gcatagcct gcccaaccca gacactgacc tctactgggt caccctgtac 840
 cagtttttcc tggcctttgc cctgcctttt gtggatcatca cagccgcata cgtgaggatc 900
 ctgcagcgca tgacgtctc agtggccccc gcctcccagc gcagcatccg gctgcggaca 960
 aagaggggtga cccgcacagc catcgccatc tgtctggtct tctttgtgtg ctgggcaccc 1020
 tactatgtgc tacagctgac ccagttgtcc atcagccgcc cgaccctcac ctttgtctac 1080
 ttatacaatg cggccatcag cttgggctat gccaacagct gcctcaaccc ctttgtgtac 1140
 atcgtgctct gtgagacgtt ccgcaaacgc ttggtcctgt cgggtgaagcc tgcagcccag 1200
 gggcagcttc gcgctgtcag caacgctcag acggctgacg aggagaggac agaaagcaaa 1260
 ggcacctga 1269

<210> 6
<211> 422
<212> PRT
<213> Human

<400> 6
 Met Ser Val Gly Ala Met Lys Lys Gly Val Gly Arg Ala Val Gly Leu
 1 5 10 15
 Gly Gly Gly Ser Gly Cys Gln Ala Thr Glu Glu Asp Pro Leu Pro Asn
 20 25 30
 Cys Gly Ala Cys Ala Pro Gly Gln Gly Gly Arg Arg Trp Arg Leu Pro
 35 40 45
 Gln Pro Ala Trp Val Glu Gly Ser Ser Ala Arg Leu Trp Glu Gln Ala
 50 55 60
 Thr Gly Thr Gly Trp Met Asp Leu Glu Ala Ser Leu Leu Pro Thr Gly
 65 70 75 80
 Pro Asn Ala Ser Asn Thr Ser Asp Gly Pro Asp Asn Leu Thr Ser Ala
 85 90 95
 Gly Ser Pro Pro Arg Thr Gly Ser Ile Ser Tyr Ile Asn Ile Ile Met
 100 105 110
 Pro Ser Val Phe Gly Thr Ile Cys Leu Leu Gly Ile Ile Gly Asn Ser
 115 120 125
 Thr Val Ile Phe Ala Val Val Lys Lys Ser Lys Leu His Trp Cys Asn
 130 135 140
 Asn Val Pro Asp Ile Phe Ile Ile Asn Leu Ser Val Val Asp Leu Leu
 145 150 155 160
 Phe Leu Leu Gly Met Pro Phe Met Ile His Gln Leu Met Gly Asn Gly
 165 170 175
 Val Trp His Phe Gly Glu Thr Met Cys Thr Leu Ile Thr Ala Met Asp
 180 185 190
 Ala Asn Ser Gln Phe Thr Ser Thr Tyr Ile Leu Thr Ala Met Ala Ile
 195 200 205
 Asp Arg Tyr Leu Ala Thr Val His Pro Ile Ser Ser Thr Lys Phe Arg
 210 215 220

Lys Pro Ser Val Ala Thr Leu Val Ile Cys Leu Leu Trp Ala Leu Ser
 225 230 235 240
 Phe Ile Ser Ile Thr Pro Val Trp Leu Tyr Ala Arg Leu Ile Pro Phe
 245 250 255
 Pro Gly Gly Ala Val Gly Cys Gly Ile Arg Leu Pro Asn Pro Asp Thr
 260 265 270
 Asp Leu Tyr Trp Phe Thr Leu Tyr Gln Phe Phe Leu Ala Phe Ala Leu
 275 280 285
 Pro Phe Val Val Ile Thr Ala Ala Tyr Val Arg Ile Leu Gln Arg Met
 290 295 300
 Thr Ser Ser Val Ala Pro Ala Ser Gln Arg Ser Ile Arg Leu Arg Thr
 305 310 315 320
 Lys Arg Val Thr Arg Thr Ala Ile Ala Ile Cys Leu Val Phe Phe Val
 325 330 335
 Cys Trp Ala Pro Tyr Tyr Val Leu Gln Leu Thr Gln Leu Ser Ile Ser
 340 345 350
 Arg Pro Thr Leu Thr Phe Val Tyr Leu Tyr Asn Ala Ala Ile Ser Leu
 355 360 365
 Gly Tyr Ala Asn Ser Cys Leu Asn Pro Phe Val Tyr Ile Val Leu Cys
 370 375 380
 Glu Thr Phe Arg Lys Arg Leu Val Leu Ser Val Lys Pro Ala Ala Gln
 385 390 395 400
 Gly Gln Leu Arg Ala Val Ser Asn Ala Gln Thr Ala Asp Glu Glu Arg
 405 410 415
 Thr Glu Ser Lys Gly Thr
 420

<210> 7
 <211> 207
 <212> DNA
 <213> Human

<400> 7
 atgtcagtgg gagccatgaa gaagggagtg gggagggcag ttgggcttgg aggcggcagc 60
 ggctgccagg ctacggagga agaccccctt cccaactgcg gggcttgccg tccgggacaa 120
 ggtggcaggc gctggaggct gccgcagcct gcgtgggttg aggggagctc agctcggttg 180
 tgggagcagg cgaccggcac tggctgg 207

<210> 8
 <211> 69
 <212> PRT
 <213> Human

<400> 8
 Met Ser Val Gly Ala Met Lys Lys Gly Val Gly Arg Ala Val Gly Leu
 1 5 10 15
 Gly Gly Gly Ser Gly Cys Gln Ala Thr Glu Glu Asp Pro Leu Pro Asn
 20 25 30
 Cys Gly Ala Cys Ala Pro Gly Gln Gly Gly Arg Arg Trp Arg Leu Pro
 35 40 45
 Gln Pro Ala Trp Val Glu Gly Ser Ser Ala Arg Leu Trp Glu Gln Ala
 50 55 60
 Thr Gly Thr Gly Trp
 65

<210> 9
 <211> 2483
 <212> DNA
 <213> Human

<400> 9
 atgtcagtgg gagccatgaa gaagggagtg gggagggcag ttgggcttgg aggcggcagc 60

ggctgccagg	ctacggagga	agacccccctt	cccaactgcg	gggcttgccg	tccgggacaa	120
ggtggcaggc	gctggaggct	gccgcagcct	gcgtgggtgg	aggggagctc	agctcggttg	180
tgggagcagg	cgaccggcac	tggctggatg	gacctggaag	cctcgctgct	gccactgggt	240
cccaacgcca	gcaacacctc	tgatggcccc	gataacctca	cttcggcagg	tgagttgact	300
gggagccctc	cctcctctgg	gctgtgggtg	gaaaatggga	aggtttcacc	cctgagccaa	360
actgcttggtg	aaactttatc	acagtctctt	gggacaagat	ctgtggtctg	ctttgctctg	420
aggggcaggga	gaaaaggggg	caatggtccg	caggggcaga	cgggcaggag	cagagcaggg	480
ggcgaaggca	tattcagaat	ggcaagggaag	ggggggccagc	cgtgagacag	caggggaagg	540
ctcgctgctg	ggttccaaag	atgcttggca	gaaaaaatc	caggctggaa	aagcaagcga	600
gagaagctgg	agggtggtat	gtgggagaca	gctgggggct	cactcctgca	ctgttagcct	660
cagcttttta	ctcccacttg	gatgatgagg	tctgagacat	ccttactgcc	acctgggaga	720
ggccctggga	agggaagact	tcacagagcc	atgaggggat	taacttttct	ggtgaattaa	780
ggttctctga	atttccagag	ctgcgtggcc	ctgggtattc	agctttggaag	gagaaaggaa	840
ggaaggaaaa	gaggaaaggc	ttatgtagat	aatttttcca	ggctgctgag	ctccaacaga	900
cagttttctgt	ctctgcttca	ctcaagaagc	ccaggctcag	aagataccaa	tcaaggaaat	960
ccccgctagg	aagcctgggg	tagggagagc	tgctggcttg	accagggcac	agccggcaaa	1020
agcctctaca	agacagtcac	ccacagatat	gccccagaat	cagtacacag	tttccaacca	1080
gagatctcca	aaatgaaaca	ctcagggcta	cacataggaa	aagcacgcac	acacacacac	1140
acacacatac	acagacactt	acttttgtgt	ccttctggct	atgctgacga	gttttctctg	1200
tgaagcccg	ggctcacaga	gtaatctctg	cagacaactg	tggttcttgc	ctctgggtgc	1260
tgcaggaggc	aggcatgttg	tgtccttcca	agacagatgg	ctcagggcac	tctggttagga	1320
ttcaccagga	aactcatgga	gaagggaaaa	gggacaagat	tagcaacagt	gaagggaggg	1380
agaatggtgg	gagaggattc	cagatgaacg	gtgggtcgct	ggaggctgag	catgccagca	1440
ggatgtcagt	tctcagagca	aagcccattg	caaacagcca	acgcttgctc	cttctgtccc	1500
caggatcacc	tctcgcacg	gggagcatct	cctacatcaa	catcatcatg	ccttcgggtg	1560
tcggcaccat	ctgcctcctg	ggcatcatcg	ggaactccac	ggtcactctc	gcggctcgtg	1620
agaagtccaa	gctgcactgg	tgcaacaacg	tccccgacat	cttcatcatc	aacctctcgg	1680
tagtagatct	cctctttctc	ctgggcatgc	ccttcatgat	ccaccagctc	atgggcaatg	1740
gggtgtggca	ctttggggag	accatgtgca	ccctcatcac	ggccatggat	gccaatagtc	1800
agttcaccag	cacctacatc	ctgaccgcca	tgccatttga	ccgctacctg	gccactgtcc	1860
accccatctc	ttccacgaag	ttccggaagc	cctctgtggc	caccttggtg	atctgcctcc	1920
tgtgggcccc	ctccttcate	agcatcacc	ctgtgtggct	gtatgccaga	ctcatcccc	1980
tcccaggagg	tgcagtgggc	tgcggcatac	gcctgcccc	cccagacact	gacctctact	2040
ggttcaccct	gtaccagttt	ttcctggcct	ttgccctgcc	ttttgtggtc	atcacagccg	2100
catacgtgag	gatcctgcag	cgcatagcgt	cctcagtggc	ccccgcctcc	cagcgcagca	2160
tccggctgcg	gacaaagagg	gtgacccgca	cagccatcgc	catctgtctg	gtcttctttg	2220
tgtgctgggc	accctactat	gtgctacagc	tgacccagtt	gtccatcagc	cgccccgacc	2280
tcacctttgt	ctacttatac	aatgcggcca	tcagcttggg	ctatgccaac	agctgcctca	2340
acccctttgt	gtacatcgtg	ctctgtgaga	cgttccgcaa	acgcttggtc	ctgtcgggtg	2400
agcctgcagc	ccaggggcag	cttcgcgctg	tcagcaacgc	tcagacggct	gacgaggaga	2460
ggacagaaag	caaaggcacc	tga				2483

<210> 10
 <211> 12
 <212> DNA
 <213> Human

<220>
 <221> misc_feature
 <222> (1)...(12)
 <223> r = A or G

<400> 10
 gccgcrrcca tc

12

**DECLARATION AND
POWER OF ATTORNEY
FOR UTILITY OR DESIGN
PATENT APPLICATION
(37 CFR 1.63)**Declaration
Submitted
with Initial
Filing

OR

Declaration
Submitted after Initial
Filing (surcharge
(37 CFR 1.16 (e))
required)

Attorney Docket Number

20493P

First Named Inventor

Howard, Andrew D.

COMPLETE IF KNOWN

Application Number

Filing Date

Group Art Unit

Examiner Name

As a below named inventor, I hereby declare that:

My residence, post office address, and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

MELANIN-CONCENTRATING HORMONE RECEPTOR

(Title of the Invention)

the specification of which



is attached hereto

OR



was filed on (MM/DD/YYYY)

07/10/2000

as United States Application Number or PCT International

Application Number PCT/US00/18733 and was amended on (MM/DD/YYYY) (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment specifically referred to above.

I acknowledge the duty to disclose to the Patent and Trademark Office all information known to me to be material to patentability as defined in 37 CFR 1.56.

I hereby claim foreign priority benefits under 35 U.S.C. 119(a)-(d) or 365(b) of any foreign application(s) for patent or inventor's certificate, or 365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or of any PCT international application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application Number(s)	Country	Foreign Filing Date (MM/DD/YYYY)	Attorney Docket Number	Priority Claimed?	
				YES	NO
				<input type="checkbox"/>	<input type="checkbox"/>
				<input type="checkbox"/>	<input type="checkbox"/>
				<input type="checkbox"/>	<input type="checkbox"/>
				<input type="checkbox"/>	<input type="checkbox"/>



Additional foreign application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto:

I hereby claim the benefit under 35 U.S.C. 119(e) of any United States provisional application(s) listed below.

Application Number(s)	Filing Date (MM/DD/YYYY)	Attorney Docket Number
60/143,706	07/14/1999	20493PV

DECLARATION AND POWER OF ATTORNEY for Utility or Design Patent Application

I hereby claim the benefit under 35 U.S.C 120 of any United States application(s), or 365(c) of any PCT international application designating the United States of America, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT international application in the manner provided by the first paragraph of 35 U.S.C. 112, I acknowledge the duty to disclose information known to me to be material to patentability as defined in 37 CFR 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

U.S. Parent Application or PCT Parent Application Number	Parent Filing Date (MM/DD/YYYY)	Parent Patent Number (if applicable)
PCT/US00/18733	07/10/2000	WO 01/05947 A1

☐ Additional U.S. or PCT international application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto.

As a named inventor, I hereby appoint, respectively and individually, as my attorneys or agents with full power of substitution and revocation, the following registered practitioner(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

☐ Customer Number

OR

☒ Registered practitioner(s) name/registration number listed below

Place Customer Number
Bar Code Label here

Name	Registration Number	Name	Registration Number
Sheldon O. Heber	38,179	Jack L. Tribble	32,633

Direct all correspondence to: ☒ Customer Number or Bar Code Label

000210

Name	Sheldon O. Heber				
Address	Merck & Co., Inc. - Patent Department				
Address	P.O. Box 2000, RY60-30				
City	Rahway	State	NJ	ZIP	07065-0907
Country	USA	Telephone	(732)594-1958	Fax	(732)594-4720

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Name of Sole or First Inventor:

☐ A petition has been filed for this unsigned inventor

Given Name (first and middle [if any])

Family Name or Surname

Andrew D.

Howard

Inventor's
Signature

Date

12/05/01

Residence:
City

Park Ridge

State

NJ

Country

USA

Citizenship

US

Post Office
Address

Merck & Co., Inc., P.O. Box 2000

City

Rahway

State

NJ

ZIP

07065-0907

☐ Additional inventors are being named on the _____ supplemental Additional Inventors(s) sheet(s) PTO/SB/02A attached hereto.